

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 October 2002 (31.10.2002)

PCT

(10) International Publication Number  
**WO 02/085402 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 38/00**,  
38/16

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,  
YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US02/12891

(22) International Filing Date: 24 April 2002 (24.04.2002)

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

(26) Publication Language: English

**Published:**

(30) Priority Data:  
60/286,240 24 April 2001 (24.04.2001) US

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(71) Applicant: THE GENERAL HOSPITAL CORPORATION [US/US]; 32 Fruit Street, Boston, MA 02114 (US).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(72) Inventor: PODOLSKY, Daniel, K.; 157 Edmunds Road, Wellesley Hills, MA 02181 (US).

(74) Agent: CLARK, Paul, T.; Clark & Elbing LLP, 101 Federal Street, Boston, MA 02110 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,



**WO 02/085402 A1**

(54) Title: METHODS AND COMPOSITIONS FOR TREATING ORAL AND EOSOPHAGEAL LESIONS

(57) Abstract: The invention features methods and compositions for treating or preventing lesions of the upper alimentary canal, particularly oral aphthous or mucositis lesions. Intestinal trefoil peptides are administered in effective concentrations either alone or in combination with different therapeutic agents.

5

## METHODS AND COMPOSITIONS FOR TREATING ORAL AND ESOPHAGEAL LESIONS

### Field of the Invention

This invention provides methods and compositions for treating lesions of  
10 the upper alimentary canal including the oral cavity and esophagus.

### Background of the Invention

Oral mucositis is the destruction of the oral mucosal epithelium which results in erythema, ulcerations, and pain in the oral cavity. Mucositis often arises  
15 as a complication of antineoplastic therapy such as cancer chemotherapy or radiotherapy. The painful ulcerative lesions of mucositis can cause patients to restrict their oral intake of food and liquids; as a result, they lose weight and suffer from dehydration. Severe mucositis can necessitate the de-escalation or the complete interruption of anti-neoplastic therapy. Chemotherapy or radiotherapy  
20 can also disrupt mucosal epithelium more distally in the gastrointestinal tract including the esophagus, stomach, and small and large intestines, resulting in pain and organ dysfunction (i.e., diarrhea).

The mucositis lesions are also sites of secondary infections, acting as portals of entry for endogenous oral microorganisms; a particularly serious  
25 concern in patients who are immunocompromised. Mucositis is therefore a significant risk factor for chronic debilitating local infections (e.g. yeast (*Candida*) infections) as well as life-threatening systemic infection (septicemia). Patients with mucositis and neutropenia have a relative risk of septicemia that is at least four times greater than that of individuals without mucositis.

30 Aphthous ulcers of the mouth (or aphthous stomatitis) are a common and painful problem; approximately 10% of the population suffers from these mouth sores at one time or another. The cause of outbreaks of aphthous sores are not

well understood, although they tend to be associated with stress and minor injury to the inside of the mouth. No satisfactory treatments are available, although topical application of steroids provides relief for some patients.

5

### Summary of the Invention

This invention features a method for treating a lesion of the upper alimentary canal in a mammal by administering to the mammal a therapeutically effective amount of an intestinal trefoil peptide. Preferably, the mammal is a human.

In preferred embodiments, the intestinal trefoil peptide is spasmolytic polypeptide (SP), pS2, or intestinal trefoil factor (ITF). More preferably, the intestinal trefoil peptide is ITF.

Lesions of the upper alimentary canal such as mucositis, aphthous stomatitis, and gingivitis can be treated by the methods of this invention. Additionally, lesions of the upper alimentary canal that result from antineoplastic therapy (i.e., chemotherapy or radiotherapy), Behcet's Disease, biopsy, surgery, tumor resection, thermal or chemical burns, tooth extraction, trauma from any cause, or lesions caused by microbial (i.e., bacterial, viral, or fungal) infection are also amenable to treatment.

In preferred embodiments, the patient is also administered a second therapeutic agent. Preferred second therapeutic agents include anti-inflammatory agents, antibacterial agents (i.e., penicillins, cephalosporins, tetracyclines, or aminoglycosides), antifungal agents (i.e., nystatin or amphotericin B), antiviral agents (i.e., acyclovir), topical antiseptics (i.e., povidone-iodine), analgesics (i.e., lidocaine or benzocaine), or steroids (i.e., triamcinolone or hydrocortisone). Preferably, the second therapeutic agent is administered within 3 days, 1 day, 12 hours, 1 hour, or simultaneously with the intestinal trefoil peptide. The second therapeutic agent can be present in the same pharmaceutical composition as the intestinal trefoil peptide.

The invention also features pharmaceutical compositions suitable for delivering an intestinal trefoil peptide to the upper alimentary canal. Preferably, the pharmaceutical composition is an oral spray, an oral rinse (mouthwash), an ointment, a paste, a cream, a gel, chewing gum, a chewable tablet, a lozenge, or a 5 bioerodabile film. In one embodiment, the pharmaceutical compositions use bioerodabile microspheres to encapsulate one or more of the therapeutic agents. In preferred embodiments of an oral spray, rinse, ointment, paste, gel, or bioerodabile film, a mucoadhesive or viscosity-enhancing agent is present.

In other preferred embodiments, the intestinal trefoil peptide of the 10 pharmaceutical composition is SP, pS2, or ITF. More preferably, the intestinal trefoil peptide is ITF. In other preferred embodiments, the pharmaceutical composition further contains a second therapeutic. Preferred second therapeutic agents include anti-inflammatory agents, antibacterial agents (i.e., penicillins, cephalosporins, tetracyclines, or aminoglycosides), antifungal agents (i.e., nystatin 15 or amphotericin B), antiviral agents (i.e., acyclovir), topical antiseptics (i.e., povidone-iodine), analgesics (i.e., lidocaine or benzocaine), or steroids (i.e., triamcinolone or hydrocortisone).

By “intestinal trefoil peptide” is meant all mammalian homologs of human spasmolytic polypeptide (SP; also known as TFF2), human pS2 (also known as 20 TFF1) and human intestinal trefoil factor (ITF; also known as TFF3), and biologically active fragments thereof. Homologs of the trefoil peptides have, preferably, 70% amino acid identity to the human sequence, more preferably 85% identity, most preferably 95%, or even 99% sequence identity. The length of comparison sequences will generally be at least about 10 amino acid residues, 25 usually at least 20 amino acid residues, more usually at least 30 amino acid residues, typically at least 45 amino acid residues, and preferably more than 60 amino acid residues.

The term “fragment” is meant to include polypeptides that are truncations or deletions of SP, pS2 and ITF. Preferably, the fragments have 70% amino acid 30 identity to the corresponding regions of the human polypeptide sequence. More

preferably, the fragments are 85% identical, most preferably 95%, or even 99% identical to the human polypeptide sequence to which they correspond. The length of comparison sequences will generally be at least about 10 amino acid residues, usually at least 20 amino acid residues, more usually at least 30 amino acid residues, typically at least 45 amino acid residues, and preferably more than 5 60 amino acid residues.

Preferable fragments contain four cysteine residues in any positions which correspond to the cysteines at positions 25, 35, 45, 50, 51, 62, or 71, of human ITF (Figure 1), or positions 31, 41, 51, 56, 57, 68, and 82 of human pS2 (Figure 10 2). More preferably, fragments contain five cysteine residues at these positions. Most preferably, six, or even all seven cysteines are present.

Fragments of SP are meant to include truncations or deletions and preferably have 70% sequence identity to the corresponding human SP polypeptide sequence (Figure 3). More preferably, the fragments are 85% 15 identical, most preferably 95%, or even 99% identical to the human polypeptide sequence. Preferably, active fragments contain at least four cysteine residues which correspond to positions 6, 8, 19, 29, 34, 35, 46, 58, 68, 78, 83, 84, 95, and 104 in the human SP polypeptide. More preferably, fragments contain six cysteines which correspond to these positions. Even more preferable are 20 fragments that contain eight cysteines. Most preferable are fragments that contain cysteines at ten, twelve, or even, all fourteen positions.

It is recognized in the art that one function of the identified cysteine residues is to impart the characteristic three-loop (trefoil) structure to the protein. Accordingly, preferred fragments of ITF and pS2 have a least one loop structure, 25 more preferably, the fragments have two loop structures, and most preferably, they have three loop structures. It is equally well recognized that the native SP polypeptide has a six loop confirmation. Preferable fragments contain at least two of these loop structures, more preferably, four loop structures are conserved, and most preferably, five, or even all six loop structures are present.

By "co-formulated" is meant any single pharmaceutical composition which contains two or more therapeutic or biologically active agents.

By "pharmaceutical preparation" or "pharmaceutical composition" is meant any composition which contains at least one therapeutically or biologically active agent and is suitable for administration to a patient. For the purposes of this invention, pharmaceutical compositions suitable for delivering a therapeutic to the upper alimentary canal include, but are not limited to solutions and suspensions delivered either as an oral spray or rinse, pastes, gels, chewable tablets, sublingual, gingival, or buccal wafers and films, chewing gum, lozenges, and other compositions designed to be retained in the mouth for an extended period of time. Any of these formulations can be prepared by well known and accepted methods of art. See, for example, Remington: The Science and Practice of Pharmacy, 19<sup>th</sup> edition, (ed. AR Gennaro), Mack Publishing Co., Easton, PA, 1995.

By "microsphere" is meant a bioerodable polymeric pharmaceutical delivery device having a diameter of 5-100  $\mu\text{m}$  and a hollow central core suitable for encapsulation of the therapeutic agent. Typically, the therapeutic agent is encapsulated at the time of microsphere formulation.

By "therapeutically effective amount" is meant an amount sufficient to provide medical benefit. When administering trefoil peptides to a human patient according to the methods described herein, a therapeutically effective amount is usually about 0.1-1000 mg of intestinal trefoil peptide per day. Preferably, the patient receives, 10 mg, 100 mg, 250 mg, or 750 mg of intestinal trefoil peptide each day. The total daily does can be divided into multiple individual doses.

By "upper alimentary canal" is meant the portion of the digestive system proximal to the cardiac sphincter (cardioesophageal sphincter) of the stomach. Specifically, the upper alimentary canal is meant to include the oral cavity and associated structures (e.g., the tongue, gingival and sublingual tissues, and the hard and soft palates) and the esophagus.

By "biologically active," when referring to an intestinal trefoil peptide, fragment, or homolog is meant any polypeptide that exhibits an activity common to its related, naturally occurring family member, and that the activity is common to the family of naturally occurring intestinal trefoil peptides. An example of a 5 biological activity common to the family of trefoil peptides is the ability to alter gastrointestinal motility in a mammal.

By "isolated DNA" is meant DNA that is free of the genes which, in the naturally-occurring genome of the organism from which the given DNA is derived, flank the DNA. Thus, the term "isolated DNA" encompasses, for 10 example, cDNA, cloned genomic DNA, and synthetic DNA.

By "treating" is meant administering a pharmaceutical composition for prophylactic and/or therapeutic purposes. The active ingredients of the pharmaceutical composition can treat the primary indication (i.e., epithelial lesion) or secondary symptoms (e.g., concomitant infection, pain, or 15 inflammation).

By "analgesic" is meant an agent which relieves pain by elevating the pain threshold without significantly disturbing the consciousness of the patient.

By "antimicrobial agent" is meant any compound that alters the growth of bacteria or fungi cells, or viruses whereby growth is prevented, stabilized, or 20 inhibited, or wherein the microbes are killed. In other words, the antimicrobial agents can be microbiocidal or microbiostatic.

By "thermal burn" is meant injury to or destruction of at least the epithelial cell layer caused by exposure to excessive temperature. Thermal burns of the upper alimentary canal are usually caused by ingestion of overly-heated foods and 25 liquids, or inhalation of super-heated air. Thermal burns are meant to include, but are not limited to, burns classified as first degree, second degree, and third degree burns.

By "chemical burn" is meant injury to or destruction of at least the epithelial cell layer caused by exposure to noxious chemicals. Typically, 30 chemical exposures of the upper alimentary canal are caused by inhalation or

ingestion.

By "antineoplastic therapy" is meant any treatment regimen used to treat cancer. Typical antineoplastic therapies include chemotherapy and radiation therapy.

5

Brief Description of Drawings

Figure 1 is the amino acid sequence of a human intestinal trefoil factor (ITF; Accession No. BAA95531; SEQ ID NO: 1).

Figure 2 is the amino acid sequence of a human pS2 protein (Accession 10 No. NP\_003216; SEQ ID NO: 2).

Figure 3 is the amino acid sequence of human spasmolytic polypeptide (SP; Accession No. 1909187A; SEQ ID NO:3).

Figure 4 is a cDNA sequence encoding a human intestinal trefoil factor (SEQ ID NO: 4).

Figure 5 is a cDNA sequence encoding a human pS2 protein (SEQ ID NO: 15 5).

Figure 6 is a cDNA sequence encoding a human spasmolytic polypeptide (SEQ ID NO: 6).

Figure 7 is the nucleotide sequence of a gene encoding human intestinal 20 trefoil factor (locus 10280533:52117-55412; SEQ ID NO: 7).

Figure 8 is the nucleotide sequence of a gene encoding human pS2 protein (locus 10280533:16511-21132; SEQ ID NO: 8).

Figure 9 is the nucleotide sequence of a gene encoding human spasmolytic polypeptide (locus 10280533:957-5208; SEQ ID NO: 9).

25

Detailed Description

The invention provides methods and compositions useful for the treatment of a wide range of lesions of the upper alimentary canal. The intestinal trefoil peptide therapy of this invention is particularly useful for treating epithelial 30 lesions of the oral and esophageal mucosa, tongue, and gingival tissue.

Mammalian trefoil peptides were discovered in 1982. One of the mammalian trefoil peptides, human intestinal trefoil factor (ITF; TFF3), has been characterized extensively, and is described in U.S. Patent Nos. 6,063,755, and 6,221,840, hereby incorporated by reference. The other two known human 5 intestinal trefoil peptides are spasmolytic polypeptide (SP; TFF2) and pS2 (TFF1). Trefoil peptides, described extensively in the literature (e.g., Sands *et al.*, Annu. Rev. Physiol. 58: 253-273 (1996), hereby incorporated by reference), are expressed in the gastrointestinal tract and have a three-loop structure formed by intrachain disulfide bonds between conserved cysteine residues. These peptides 10 protect the intestinal tract from injury and can be used to treat intestinal tract disorders such as peptic ulcers and inflammatory bowel disease. Homologs of these human peptides have been found in a number of non-human animal species. All members of this protein family, both human and non-human, are referred to herein as trefoil peptides. Human ITF will be referred to most extensively in this 15 application; however, the activity of human ITF is common to each of the mammalian intestinal trefoil peptides.

We have discovered that epithelial lesions of the upper alimentary canal including the oral and esophageal mucosa, tongue, and gingival tissue can be treated by local administration of intestinal trefoil peptides. Thus, trefoil peptide 20 therapy, according to the methods of this invention, can be delivered in any pharmaceutical composition which is useful for delivering therapeutics to the upper alimentary canal.

### ***Pharmaceutical Preparations***

#### **Oral Sprays, Rinses, and Emulsions**

Spray systems are particularly useful for delivering therapeutics to the upper alimentary canal. Suitable spray delivery systems include both pressurized and non-pressurized (pump actuated) delivery devices. The intestinal trefoil peptide-containing solution, delivered as an oral spray, is preferably an aqueous 30 solution; however, organic and inorganic components, emulsifiers, excipients, and

agents that enhance the organoleptic properties (i.e., flavoring agents or odorants) may be included. Optionally, the solution may contain a preservative that prevents microbial growth (i.e., methyl paraben). Although water itself may make up the entire carrier, typical liquid spray formulations contain a co-solvent, for 5 example, propylene glycol, corn syrup, glycerin, sorbitol solution and the like, to assist solubilization and incorporation of water-insoluble ingredients. In general, therefore, the compositions of this invention preferably contain from about 1-95% v/v and, most preferably, about 5-50% v/v, of the co-solvent. When prepared as an spray, patients typically self-administer 1-5 times per day. The spray delivery 10 system is normally designed to deliver 50-100  $\mu$ l per actuation, and therapy may require 1-5 actuations per dose. The rheological properties of the spray formulation are optimized to allow shear and atomization for droplet formation. Additionally, the spray delivery device is designed to create a droplet size which promotes retention on mucosal surfaces of the upper alimentary canal and 15 minimize respiratory exposure.

Compositions suitable for oral sprays can also be formulated as an oral rinse or mouthwash. Administration of trefoil peptides using these formulations is typically done by swishing, gargling, or rinsing the oral cavity with the formulation. Optionally, these formulations can be swallowed, providing trefoil 20 peptide therapy to the esophagus, stomach, and/or intestines. This delivery method is particularly useful for treating patients suffering related disorders of the intestinal epithelium. For example, patients receiving antineoplastic chemotherapy, in addition to oral mucositis, frequently develop more distal lesions of the gastrointestinal tract such as lesions of the gastric and intestinal 25 epithelium. It is well known that intestinal trefoil peptides, particularly ITF, are stable at stomach pH. Thus, swallowing an intestinal trefoil peptide-containing solution designed primarily for treating oral mucositis may also benefit lesions of the lower alimentary canal (i.e., stomach and intestines).

In an alternative formulation, the intestinal trefoil peptides and/or other therapeutics can be encapsulated in bioerodable microspheres rather than being dissolved in the aqueous phase of the formulation. A wide variety of microencapsulation drug delivery systems have been developed and many share 5 similar polymeric compositions as used for bioerodable films (described below). Polymers commonly used in the formation of microspheres include, for example, poly- $\epsilon$ -caprolactone, poly( $\epsilon$ -caprolactone-Co-DL-lactic acid), poly(DL-lactic acid), poly(DL-lactic acid-Co-glycolic acid) and poly( $\epsilon$ -caprolactone-Co-glycolic acid) (see, for example, Pitt *et al.*, J. Pharm. Sci., 68:1534, 1979).

10 Microspheres can be made by procedures well known in the art including spray drying, coacervation, and emulsification (see for example Davis *et al.* Microsphere and Drug Therapy, Elsevier, 1984; Benoit *et al.* Biodegradable Microspheres: Advances in Production Technologies, Chapter 3, Ed. Benita, S, Dekker, New York, 1996; Microencapsulation and Related Drug Processes, Ed. 15 Deasy, Dekker, 1984, New York; U.S. Patent No. 6,365,187). Preferably, the microspheres are bioadhesive or are prepared in formulations containing a bioadhesive excipient.

Other technical features of the intestinal trefoil peptide-containing solutions are easily modified to suit the specific pharmaceutical formulation and 20 the clinical indication being treated. For example, the pH and osmolality of the formulation may be adjusted to confer trefoil peptide stability, while minimizing oral irritancy and sensitivity.

#### Ointments, Pastes, and Gels

25 Lesions of the oral and esophageal epithelium caused by trauma are amenable to trefoil peptide therapy delivered as an ointment, paste, or gel. The viscous nature of these types of preparations allows for direct application into the wound site. Optionally, the wound site can be covered with a dressing to retain the trefoil peptide-containing composition, protect the lesion from trauma, and/or 30 absorb exudate. As discussed further below, these preparations are particularly

useful to restore epithelial integrity following traumatic surgical procedures such as, for example, tooth extraction, tissue biopsy, or a tumor resection. Such viscous formulations may also have a local barrier effect thereby reducing irritation and pain.

5

### Mucoadhesives

A mucoadhesive excipient can be added to any of the previously described pharmaceutical compositions. The mucoadhesive formulations coat the upper alimentary canal providing protection, inhibiting irritation, and accelerating 10 healing of inflamed or damaged tissue. Mucoadhesive formulations also promote prolonged contact of the intestinal trefoil peptide with the mucosal epithelium. Mucoadhesive formulations suitable for use in pharmaceutical preparations delivered by mouth are well known in the art (e.g., U.S. Patent No. 5,458,879). Particularly useful mucoadhesives are hydrogels composed of about 0.05-20% of 15 a water-soluble polymer such as, for example, poly(ethylene oxide), poly(ethylene glycol), poly(vinyl alcohol), poly(vinyl pyrrolidine), poly(acrylic acid), poly(hydroxy ethyl methacrylate), hydroxyethyl ethyl cellulose, hydroxy ethyl cellulose, chitosan, and mixtures thereof. These polymeric formulations can also contain a dispersant such as sodium carboxymethyl cellulose (0.5-5.0%).

20 Other preferred mucoadhesive excipients for liquid compositions are ones that allow the composition to be administered as a flowable liquid but will cause the composition to gel in the upper alimentary canal, thereby providing a bioadhesive effect which acts to hold the therapeutic agents at the lesion site for an extended period of time. The anionic polysaccharides pectin and gellan are 25 examples of materials which when formulated into a suitable composition will gel in the upper alimentary canal, owing to the presence of cations in the mucosal and salivary fluids. The liquid compositions containing pectin or gellan will typically consist of 0.01-20% w/v of the pectin or gellan in water or an aqueous buffer system.

30

Other useful compositions which promote mucoadhesion and prolonged therapeutic retention in the upper alimentary canal are colloidal dispersions containing 2-50% colloidal particles such as silica or titanium dioxide. Such formulations form as a flowable liquid with low viscosity suitable as a mouthwash or for generating a fine mist. However, the particles interact with glycoprotein, especially mucin, transforming the liquid into a viscous gel, providing effective mucoadhesion (e.g., U.S. Patent Nos. 5,993,846 and 6,319,513).

### Bioerodable Film Delivery Devices

The most simple bioerodable devices contain the therapeutic agent(s) incorporated into a solid, usually lipid-containing, film or tablet. The device is formulated to remain solid at room temperature, but melt at body temperature, releasing the incorporated therapeutics. Suitable formulations of this type include, for example, cocoa butter.

Polymeric film devices provide several advantages for therapeutic delivery to the oral cavity. Unlike rinses, pastes, gels, and other flowable compositions, a film device can reside for prolonged periods of time (i.e., hours to days) in the oral cavity and provide sustained release throughout its residency. Typically, the film is partially or completely bioerodable and contains a mucoadhesive layer to fasten the film to the oral mucosa. Film devices, in addition to its use for delivering therapeutics, can also provide protection against mechanical injury or microbial infection of a lesion site. This physical barrier function is particularly advantageous when treating conditions such as mucositis or aphthous stomatitis. Additionally, as discussed further below, a film device can be used to release trefoil peptide therapy directly onto the underlying mucosa, into the lumen of the oral cavity, or a combination of both.

Film devices consist of at least two layers; a mucoadhesive layer suitable for attaching the film to the oral mucosa and a bulk layer which contains the active therapeutic(s). Many suitable mucoadhesives are known in the art and are discussed above. Optionally, one or more therapeutics can also be provided in the

adhesive layer.

The bulk layer of the composite delivery device may be made of one or more bioerodable polymeric materials. Suitable polymers include, for example, starch, gelatin, polyethylene glycol, polypropylene glycol, polyethylene oxide, 5 copolymers of ethylene oxide and propylene oxide, copolymers of polyethylene glycol and polypropylene glycol, polytetramethylene glycol, polyether urethane, hydroxyethyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, alginate, collagen, polylactide, poly(lactide-co-glycolide) (PLGA), calcium polycarbophil, polyethylmethacrylate, cellulose 10 acetate, propylene glycol, polyacrylic acid, crosslinked polyacrylic acid, hydroxyethyl methacrylate/methyl methacrylate copolymer, silicon/ethyl cellulose/polyethylene glycol, urethane polyacrylate, polystyrene, polysulfone, polycarbonate, polyorthoesters, polyanhydrides, poly(amino acids), partially and completely hydrolyzed alkylene-vinyl acetate copolymers, polyvinyl chloride, 15 polymers of polyvinyl acetate, polyvinyl alkyl ethers, styrene acrylonitrile copolymers, poly(ethylene terphthalate), polyalkylenes, poly(vinyl imidazole), polyesters and combinations of two or more of these polymers.

A particularly useful bulk layer polymer consists of PLGA and ethyl cellulose. PLGA is bioerodable and can be formulated to degrade over a wide 20 range of conditions and rates. Ethyl cellulose is a water-insoluble polymer that can act as a plasticizer for the PLGA when a film is formed, but will be eroded in a bodily fluid. Due to its water-insolubility, it also has an effect on the degree and rate of swelling of the resultant film.

An optional third layer which is impermeable to the trefoil peptide can also 25 be added to the wafer. Preferably, this barrier layer is also bioerodable. Suitable barrier layer polymers include ethyl cellulose, poly(acrylic acid), or other polyelectrolytes. In one configuration, the barrier layer is placed on the opposite side of the bulk layer relative to the adhesive layer, thereby directing the released therapeutic agent onto the contacted epithelium rather than being diluted in the 30 luminal fluid. This configuration is particularly useful for treating discrete

lesions (i.e., mucositis or aphthous stomatitis) of the tongue, sublingual tissue, or buccal mucosa. In an alternative configuration of the film device, the barrier layer is placed between the bulk layer and the adhesive layer. This configuration directs therapeutic release into the lumen of the oral cavity and is useful for 5 treating more diffuse lesions of the tongue, oral cavity, and esophagus. The configuration is also useful for delivering therapeutics which are cytotoxic when administered at high concentrations because it has the effect of shielding the underlying tissue from direct contact with the therapeutic-containing film.

10        Chewable Tablets, Lozenges, and Confectionaries

Preparing a trefoil peptide-containing composition as a chewable tablet, lozenge, or a confectionary such as chewing gum provides several advantages to traditional drug delivery vehicles. First, prolonged contact and sustained release at the target site (mouth and esophagus) is achieved. Second, such formulations 15 often results in higher patient compliance, especially when administering trefoil peptides to children.

Formulations for chewable tablets are well known and typically contain a base of sugar, starch, or lipid and a flavoring agent. An exemplary formulation for a chewable tablet is provided below.

20        *Chewable ITF Tablet Formulation (per tablet)*

Intestinal trefoil factor – 300 mg  
Mannitol – 675 mg  
Microcrystalline cellulose – 75mg  
Corn starch – 30 mg  
25        Calcium sterate – 22 mg  
Flavoring Agent (i.e., sodium saccharin or peppermint oil)

The incorporation of therapeutics into chewing gum and other confectionary style formulations is known in the art (e.g., U.S. Patent No. 30        5,858,391).

***Therapeutics Agents*****Trefoil Peptides**

In preferred embodiments, the trefoil peptide is a human trefoil peptide. More preferably, it is human intestinal trefoil factor (ITF), spasmolytic 5 polypeptide (SP), or pS2. Most preferably, the trefoil peptide is human ITF.

The trefoil peptides are present in the compositions of the invention at a concentration of between 0.1-1000 mg/ml, depending on the nature and condition of the lesion being treated, the anticipated frequency and duration of therapy, and the type of pharmaceutical composition used to deliver the trefoil peptide.

10 Typically, therapy is designed to deliver 0.1-500 mg of trefoil peptide per day to the patient.

**Anti-Inflammatory Agents**

Any suitable anti-inflammatory agent can be formulated in the 15 compositions of the invention, at concentrations known for these agents. Many of the most useful anti-inflammatory agents also have analgesic and/or antipyretic properties. Anti-inflammatory agents suitable for co-formulation with a trefoil peptide include, for example, acetaminophen, aspirin (acetylsalicylic acid), ibuprofen, phenylbutazone, indomethacin, sulindac, diclofenac, and naproxen.

20

**Antimicrobial Agents**

Any of the many known microbial agents can be used in the compositions of the invention at concentrations generally used for these agents. Antimicrobial agents include antibacterials, antifungals, antivirals, and other topical antiseptics.

25 Examples of antibacterial agents (antibiotics) include the penicillins (e.g., penicillin G, ampicillin, methicillin, oxacillin, and amoxicillin), the cephalosporins (e.g., cefadroxil, ceforanid, cefotaxime, and ceftriaxone), the tetracyclines (e.g., doxycycline, minocycline, and tetracycline), the aminoglycosides (e.g., amikacin, gentamycin, kanamycin, neomycin, 30 streptomycin, and tobramycin), the macrolides (e.g., azithromycin, clarithromycin,

and erythromycin), the fluoroquinolones (e.g., ciprofloxacin, lomefloxacin, and norfloxacin), and other antibiotics including chloramphenicol, clindamycin, cycloserine, isoniazid, rifampin, and vancomycin.

Antiviral agents are substances capable of destroying or suppressing the  
5 replication of viruses. Examples of anti-viral agents include 1,-D-ribofuranosyl-  
1,2,4-triazole-3 carboxamide, 9->2-hydroxy-ethoxy methylguanine,  
adamantanamine, 5-iodo-2'-deoxyuridine, trifluorothymidine, interferon, adenine  
arabinoside, protease inhibitors, thymidine kinase inhibitors, sugar or  
glycoprotein synthesis inhibitors, structural protein synthesis inhibitors,  
10 attachment and adsorption inhibitors, and nucleoside analogues such as acyclovir,  
penciclovir, valacyclovir, and ganciclovir.

Antifungal agents include both fungicidal and fungistatic agents such as,  
for example, amphotericin B, butylparaben, clindamycin, econazole, fluconazole,  
flucytosine, griseofulvin, nystatin, and ketoconazole.

15 Topical antiseptics include agents such as, for example, povidone-iodine  
and benzalkonium chloride.

#### Analgesics and Anesthetics

Any of the commonly used topical analgesics can be used in the  
20 compositions of the invention. The analgesic is present in an amount such that  
there is provided to the oral lesion a topical concentration of between one-half and  
five percent concentration for lidocaine (5-50 mg/ml in 20-40 ml per dose of  
liquid). Examples of other useful anesthetics include procaine, lidocaine,  
tetracaine, dibucaine, benzocaine, p-butylaminobenzoic acid 2-(diethylamino)  
25 ethyl ester HCl, mepivacaine, piperocaine, and dyclonine.

Other analgesics include opioids such as, for example, morphine, codeine,  
hydrocodone, and oxycodone. Any of these analgesics may also be co-formulated  
with other compounds having analgesic or anti-inflammatory properties, such as  
acetaminophen, aspirin, and ibuprofen.

Steroids

Steroids are commonly used to treat lesions of the upper alimentary canal.

For example, oral aphthous stomatitis is typically treated using a paste preparation of triamcinolone (0.1%), hydrocortisone, fluticasone, or beclomethasone.

5

***Conditions of the Upper Alimentary Canal Treated Using Trefoil Peptides***

Mucositis

Mucositis is a common condition of the oral cavity which is characterized by inflammation of the mucous membranes. The condition is frequently caused  
10 by antineoplastic therapy, including chemotherapy and local radiation therapy. Symptoms of mucositis include ulcerations, redness, and swelling, and is associated with epithelial cell injury and death. Patients suffering from severe mucositis are susceptible to dehydration and malnutrition because mucositis pain limits dietary intake. In severe cases, mucositis can be so debilitating that patients  
15 may require prolonged hospitalization, parenteral nutrition, and narcotic pain medication. Additionally, destruction of the mucosal epithelium increases a patient's susceptibility to local and systemic infection. Disruption of the barrier function permits entry of microorganisms and microbial products normally retained in the gut lumen. Thus, pharmaceutical preparations which reduce the  
20 adverse effects associated with chemotherapy will improve the patient's quality of life, compliance with self-medication, and may permit administration of higher chemotherapeutic doses. Typically, mucositis is treated using a trefoil peptide-containing rinse or oral spray which the patient self-administers 1-5 times per day. The aqueous solution preferably contains a mucoadhesive and an anti-  
25 inflammatory agent. Other therapeutics, such as an topical analgesic agent (e.g., lidocaine) may also be present. Alternatively, if the lesions are few in number and spatially localized, an intestinal trefoil peptide-containing film device an be placed directly over the lesions.

Tooth Extraction

Intestinal trefoil peptide-containing compositions of the invention are used to lessen complications and speed healing of the wound created by the extraction of a tooth. An oral rinse, paste, ointment, or gel, as described above, is applied to 5 the site of extraction immediately following the procedure and then 1-4 times per day, as needed, until epithelial regrowth is complete. Preferably, a topical analgesic is included in the formulation to relieve the temporary discomfort cause by the trauma of extraction. As a prophylactic measure, antibiotic agents may also be included in the formulation.

10

Gingivitis

Gingivitis is most commonly a chronic disease requiring ongoing treatment, in some cases for months or even years. The trefoil peptide-containing compositions of the invention can be employed to treat gingivitis, alone or in 15 conjunction with other treatments, particularly with an anti-microbial agent, and most commonly with an antibacterial agent. An oral intestinal trefoil peptide-containing rinse is swished in the patient's mouth at least once every 2-3 days, but as often as thrice daily, over a 3-4 week period, and the regimen is repeated as needed. Alternatively, the trefoil peptide is formulated into a gel or toothpaste. 20 In severe cases, a viscous gel or ointment having a high intestinal trefoil peptide concentration is applied directly to the wound via a pledget with a stick applicator.

Intestinal trefoil peptide-containing compositions can also be delivered in biodegradable drug delivery systems capable of formation of films applied below 25 the gum line (described in U.S. Patent Nos. 5,945,115 and 5,990,194. A biodegradable polymer, admixed with the intestinal trefoil peptide, is provided where the polymer can be injected in as a free-flowing solution below the gum line using a syringe. The polymer solution then, *in situ*, forms a solid biodegradable implant.

30

Aphthous Stomatitis

At the first indication of an outbreak of aphthous stomatitis (generally, the first twinge of pain), the patient swishes the mouth with an intestinal trefoil peptide-containing rinse, 1-4 times per day until the ulcer heals (generally 5-10 days). An intestinal trefoil peptide-containing gel can also be applied to the ulcer, in the same manner that steroid-containing gels are currently used. In addition, a gel can contain both an intestinal trefoil protein and a steroid known to be effective for aphthous stomatitis treatment. A direct application of more concentrated material can be directly applied to the wound via a pledget with a stick applicator. Alternatively, the lesion can be treated directly by applying a bioerodable film device containing both a trefoil peptide and a steroid (i.e., triamcinolone) directly to the lesion. Any formulation useful for treating aphthous stomatitis can also, optionally, contain a local anesthetic (i.e., lidocaine or benzocaine).

15

Behcet's Disease

Behcet's Disease is a rare, multi-system rheumatic disorder characterized by systemic vasculitis. One of the most frequent symptoms of Behcet's Disease is recurrent oral ulcerations which resemble aphthous lesions. Currently, treatment for Behcet's Disease is palliative, not curative. Thus, the intestinal trefoil peptides can be used to treat lesions of the upper alimentary canal in conjunction with currently available Behcet's Disease therapies including, for example, interferon alpha 2A and 2B, levamisole, cyclosporine, cyclophosphamide, and colchicine.

25

Oral Biopsy and Oral Surgery

In cases in which an oral neoplasm is suspected or known to be malignant, a biopsy or a curative resection is performed using a needle or a scalpel, resulting in an open wound. The surgical area, susceptible to infection and inflammation, is treated by rinsing with a trefoil peptide-containing solution 1-4 times per day.

Preferably, an analgesic, an anti-inflammatory, and an antibiotic are included in the formulation. Alternatively, a more concentrated gel, paste, or ointment may be directly applied to the lesion site. For post-operative treatment following resection of a malignancy, a topically active chemotherapeutic can be included in 5 the trefoil peptide-containing composition.

#### Thermal and Chemical Burns

Trauma to the upper alimentary canal is frequently caused by exposure to excessive heat or noxious chemicals. Thermal burns to the upper alimentary canal 10 are frequently mild in nature (i.e., first or second degree burns), resulting from the ingestion of overheated food or drink. More severe thermal burns of the oral mucosa and upper esophagus can be caused by inhalation of super heated air and are frequently observed in firefighters or victims of house or forest fires.

Chemical exposure can also damage the mucosa of the upper alimentary 15 canal. Mild mucosal irritations and burns are often caused by ingestion of acidic food (i.e., fruits). More severe chemical burns are usually associated with accidental industrial or occupational exposures.

The intestinal trefoil peptide-containing pharmaceutical formulations described herein are useful for treating thermal and chemical burns of the upper 20 alimentary canal. Preferably, viscous liquid or gel formulation containing a mucoadhesive is used to prolong mucosal exposure to the trefoil peptide.

Alternatively, a sustained release formulation, such as a bioerodable film, is used. Topical analgesics and antimicrobial agents are the most preferred secondary 25 therapeutics to be co-administered.

25

#### *Production of Intestinal Trefoil Peptides*

Intestinal trefoil peptides can be produced by any method known in the art for expression of recombinant proteins. Nucleic acids that encode trefoil peptides (e.g., human intestinal trefoil factor (Figure 4 and 7), human pS2 (Figure 5 and 8), 30 and human spasmolytic polypeptide (Figure 6 and 9) or fragments thereof may be

introduced into various cell types or cell-free systems for expression thereby allowing large-scale production, purification, and patient therapy.

Eukaryotic and prokaryotic trefoil peptide expression systems may be generated in which an intestinal trefoil peptide gene sequence is introduced into a 5 plasmid or other vector, which is then used to transform living cells. Constructs in which the intestinal trefoil peptide cDNA contains the entire open reading frame inserted in the correct orientation into an expression plasmid may be used for protein expression. Prokaryotic and eukaryotic expression systems allow for the expression and recovery of intestinal trefoil peptide fusion proteins in which 10 the trefoil peptide is covalently linked to a tag molecule which facilitates identification and/or purification. An enzymatic or chemical cleavage site can be engineered between the trefoil peptide and the tag molecule so that the tag can be removed following purification.

Typical expression vectors contain promoters that direct the synthesis of 15 large amounts of mRNA corresponding to the inserted intestinal trefoil peptide nucleic acid in the plasmid-bearing cells. They may also include a eukaryotic or prokaryotic origin of replication sequence allowing for their autonomous replication within the host organism, sequences that encode genetic traits that allow vector-containing cells to be selected for in the presence of otherwise toxic 20 drugs, and sequences that increase the efficiency with which the synthesized mRNA is translated. Stable long-term vectors may be maintained as freely replicating entities by using regulatory elements of, for example, viruses (e.g., the OriP sequences from the Epstein Barr Virus genome). Cell lines may also be produced that have integrated the vector into the genomic DNA, and in this 25 manner the gene product is produced on a continuous basis.

Expression of foreign sequences in bacteria, such as *Escherichia coli*, requires the insertion of an intestinal trefoil peptide nucleic acid sequence into a bacterial expression vector. Such plasmid vectors contain several elements required for the propagation of the plasmid in bacteria, and for expression of the 30 DNA inserted into the plasmid. Propagation of only plasmid-bearing bacteria is

achieved by introducing, into the plasmid, selectable marker-encoding sequences that allow plasmid-bearing bacteria to grow in the presence of otherwise toxic drugs. The plasmid also contains a transcriptional promoter capable of producing large amounts of mRNA from the cloned gene. Such promoters may be (but are 5 not necessarily) inducible promoters that initiate transcription upon induction. The plasmid also preferably contains a polylinker to simplify insertion of the gene in the correct orientation within the vector. Mammalian cells can also be used to express a trefoil peptide. Stable or transient cell line clones can be made using intestinal trefoil peptide expression vectors to produce the trefoil peptides in a 10 soluble (truncated and tagged) form. Appropriate cell lines include, for example, COS, HEK293T, CHO, or NIH cell lines.

Once the appropriate expression vectors are constructed, they are introduced into an appropriate host cell by transformation techniques, such as, but not limited to, calcium phosphate transfection, DEAE-dextran transfection, 15 electroporation, microinjection, protoplast fusion, or liposome-mediated transfection. The host cells that are transfected with the vectors of this invention may include (but are not limited to) *E. coli* or other bacteria, yeast, fungi, insect cells (using, for example, baculoviral vectors for expression in SF9 insect cells), or cells derived from mice, humans, or other animals. *In vitro* expression of 20 trefoil peptides, fusions, or polypeptide fragments encoded by cloned DNA may also be used. Those skilled in the art of molecular biology will understand that a wide variety of expression systems and purification systems may be used to produce recombinant trefoil peptides and fragments thereof. Some of these systems are described, for example, in Ausubel *et al.* (*Current Protocols in* 25 *Molecular Biology*, John Wiley & Sons, New York, NY 2000, hereby incorporated by reference).

Transgenic plants, plant cells and algae are also particularly useful for generating recombinant intestinal trefoil peptides for use in the methods and compositions of the invention. For example, transgenic tobacco plants or cultured 30 transgenic tobacco plant cells expressing an intestinal trefoil peptide can be

created using techniques known in the art (see, for example, U.S. Patent Nos. 5,202,422 and 6,140,075). Transgenic algae expression systems can also be used to produce recombinant intestinal trefoil peptides (see, for example, Chen et al., Curr. Genet. 39:365-370, 2001).

5 Once a recombinant protein is expressed, it can be isolated from cell lysates using protein purification techniques such as affinity chromatography. Once isolated, the recombinant protein can, if desired, be purified further by e.g., high performance liquid chromatography (HPLC; e.g., see Fisher, Laboratory Techniques In Biochemistry And Molecular Biology, Work and Burdon, Eds.,  
10 Elsevier, 1980).

Polypeptides of the invention, particularly short intestinal trefoil peptide fragments can also be produced by chemical synthesis using, for example, Merrifield solid phase synthesis, solution phase synthesis, or a combination of both (see, for example, the methods described in Solid Phase Peptide Synthesis, 15 2nd ed., 1984, The Pierce Chemical Co., Rockford, IL). Optionally, peptide fragments are then be condensed by standard peptide assembly chemistry.

***Example 1: Mucositis Treatment for Patients Receiving Antineoplastic Therapy***

20 Trefoil peptide therapy is initiated prior to antineoplastic therapy (i.e., chemotherapy or radiation therapy), as a prophylactic to delay or prevent the onset of mucositis. Preferably, the patient begins intestinal trefoil peptide therapy three days prior to the first dose of antineoplastic therapy. During the prophylactic stage, the patient rinses the oral cavity with an intestinal trefoil peptide-containing 25 solution. Alternatively, for convenience, the trefoil peptide is provided as a concentrated oral spray. Preferably, the patient swallows the solution, providing protection for the epithelial cells of the esophagus and lower gastrointestinal tract. Rinsing with and swallowing the intestinal trefoil peptide-containing solution continues at least twice daily until oral or esophageal mucositis is detected.

In patients with existing mucositis, epithelial healing is promoted using intestinal trefoil peptide therapy as described above. Palliative therapy is provided using benzocaine (a local anesthetic), and nystatin (an antifungal). The intestinal trefoil peptide can be co-formulated with the benzocaine and nystatin.

5 For example, the patient swishes an oral rinse solution (mouthwash), containing all therapeutic agents, 1-5 times each day. Alternatively, the trefoil peptide can be provided in a concentrated oral spray, with or without benzocaine and the nystatin is administered in an oral rinse.

The oral rinse solutions can either be swallowed or spit out. If swallowed, 10 an antacid may also be included in the formulation. Other useful therapeutics which provide palliative therapy include anti-inflammatories (e.g., ibuprofen) and other anti-microbial agents. Exemplary oral rinses useful for treating chemotherapy-induced mucositis are provided below, but are not intended to be limiting. A skilled physician or pharmacist will immediately recognize 15 appropriate substitutions, additions, and deletions that can be made to these formulations.

Rinse#1: Mix equal parts of:

- (i) diphenhydramine elixir (Benadryl®)
- (ii) kaolin-pectin suspension (Kaopectate®)
- 20 (iii) viscous lidocaine HCl (2%)
- (iv) nystatin (oral suspension; 100,000 iu/ml)
- (v) ITF (2.5 mg/ml)

preferably swallowed after swishing

25 Rinse#2: Mix equal parts of:

- (i) diphenhydramine elixir (Benadryl®)
- (ii) Maalox® (MgOH & AlOH; 40 mg/ml)
- (iii) viscous lidocaine HCl (2%)
- (iv) ITF (2.5 mg/ml)

30 preferably swallowed after swishing

*Other Embodiments*

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

What is claimed is:

CLAIMS

1. A method for treating a lesion of the upper alimentary canal of a mammal comprising administering to said patient a therapeutically effective amount of an intestinal trefoil peptide.

5

2. The method of claim 1, wherein said intestinal trefoil peptide is spasmolytic polypeptide, pS2, or intestinal trefoil factor.

10 3. The method of claim 2, wherein said intestinal trefoil peptide is intestinal trefoil factor.

4. The method of claim 1, wherein said mammal is a human.

15 5. The method of claim 1, wherein said lesion is mucositis.

6. The method of claim 1, wherein said lesion is aphthous stomatitis.

7. The method of claim 1, wherein said lesion is caused by antineoplastic therapy.

20

8. The method of claim 7, wherein said antineoplastic therapy is radiation therapy.

25 9. The method of claim 7, wherein said antineoplastic therapy is chemotherapy.

10. The method of claim 1, wherein said lesion is the result of gingivitis.

30 11. The method of claim 1, wherein said lesion is the result of tooth extraction.

12. The method of claim 1, wherein said lesion is the result of a biopsy procedure or surgical intervention.

5           13. The method of claim 1, wherein said lesion is the result of tumor resection.

14. The method of claim 1, wherein said lesion is caused by thermal or chemical burn.

10           15. The method of claim 1, wherein said lesion is caused by Behcet's Disease.

16. The method of claim 1, wherein said lesion is caused by a bacterial, viral, or fungal infection.

15           17. The method of claim 1, further comprising administering to said mammal a second therapeutic.

- 20           18. The method of claim 17, wherein said second therapeutic agent is an anti-inflammatory agent.
19. The method of claim 17, wherein said second therapeutic agent is an antibacterial agent.

25           20. The method of claim 19, wherein said antibacterial agent is a penicillin, a cephalosporin, a tetracycline, or an aminoglycoside.

- 30           21. The method of claim 19, wherein said antibacterial agent is povidone-iodine.

22. The method of claim 17, wherein said second therapeutic agent is an anti-fungal agent.

5        23. The method of claim 22, wherein said anti-fungal agent is nystatin or Amphotericin B.

24. The method of claim 17, wherein said second therapeutic agent is an anti-viral agent.

10

25. The method of claim 24, wherein said anti-viral agent is acyclovir.

26. The method of claim 17, wherein said second therapeutic agent is an analgesic.

15

27. The method of claim 26, wherein said analgesic is lidocaine or benzocaine.

20

28. The method of claim 17, wherein said second therapeutic agent is a steroid.

29. The method of claim 28, wherein said steroid is triamcinolone or hydrocortisone.

25

30. The method of claim 17, wherein said trefoil peptide and said second therapeutic are administered in the same formulation.

31. The method of claim 17, wherein said trefoil peptide and said second therapeutic are administered in different formulations.

30

32. The method of claim 31, wherein said trefoil peptide and said second therapeutic are administered within 24 hours of each other.

33. The method of claim 32, wherein said trefoil peptide and said second therapeutic are administered within one hour of each other.  
5

34. A composition suitable for therapeutic delivery to the upper alimentary canal of a mammal, said composition comprising an intestinal trefoil peptide.

10 35. The composition of claim 34, wherein said intestinal trefoil peptide is spasmolytic polypeptide, pS2, or intestinal trefoil factor.

36. The composition of claim 35, wherein said intestinal trefoil peptide is intestinal trefoil factor.  
15

37. The composition of claim 34, wherein said composition is an oral spray.

38. The composition of claim 34, wherein said composition is an oral  
20 rinse.

39. The composition of claim 34, wherein said composition is a bioerodible film.

25 40. The composition of claim 34, wherein said composition comprises microspheres.

41. The composition of claim 37, 38, 39, or 40, wherein said composition further comprises a mucoadhesive agent.  
30

42. The composition of claim 34, wherein said composition is a chewing gum, lozenge, or chewable tablet.

43. The composition of claim 34, wherein said composition further  
5 comprises a second therapeutic agent.

44. The composition of claim 43, wherein said second therapeutic agent is an anti-inflammatory agent.

10 45. The composition of claim 43, wherein said second therapeutic agent is an antibacterial agent.

46. The composition of claim 45, wherein said antibacterial agent is a penicillin, a cephalosporin, a tetracycline, or an aminoglycoside.

15 47. The composition of claim 45, wherein said antibacterial agent is povidone-iodine.

48. The composition of claim 43, wherein said second therapeutic agent is  
20 an anti-fungal agent.

49. The composition of claim 48, wherein said anti-fungal agent is nystatin or Amphotericin B.

25 50. The composition of claim 43, wherein said second therapeutic agent is an anti-viral agent.

51. The composition of claim 50, wherein said anti-viral agent is acyclovir.

30

52. The composition of claim 43, wherein said second therapeutic agent is an analgesic.

53. The composition of claim 52, wherein said analgesic is lidocaine or  
5 benzocaine.

54. The composition of claim 43, wherein said second therapeutic agent is a steroid.

10 55. The composition of claim 54, wherein said steroid is triamcinolone or hydrocortisone.

FIGURE 1

1 MLGLVLALLS SSSAEEYVGL SANQCAVPAK DRVDCGYPHV  
41 TPKECNNRGC CFDSRIPGVP WCFKPLQEAE CTF

FIGURE 2

1 MATMENKVIC ALVLVSMLAL GTLAEAQETET CTVAPRERQN  
41 CGFPGVTPSQ CANKGCCFDD TVRGVPWCFY PNTIDVPPEE  
81 ECEF

FIGURE 3

1 EKPSPCQCSR LSPHNRTNCG FPGITSDQCF DNGCCFDSSV  
41 TGVPWCFHPL PKQESDQCVM EVSDRRNCGY PGISPEECAS  
81 RKCCFSNFIF EVPWCFFPNS VEDCHY

FIGURE 4

1 atgctgggc tggcctggc cttgctgtcc tccagctctg ctgaggagta cgtgggcctg  
61 tctgcaaacc agtgtccgt gccagccaag gacagggtgg actgcggcta cccccatgtc  
121 acccccaagg agtgcaacaa ccggggctgc tgcttgact ccaggatccc tggagtgcct  
181 tggtgtttca agccctgca ggaagcagaa tgcaccccttct ga

FIGURE 5

1 atggccacca tggagaacaa ggtgatctgc gccctggtcc tggtgtccat gctggccctc  
61 ggcaccctgg ccgaggccca gacagagacg tgtacagtgg ccccccgtga aagacagaat  
121 tgtggtttc ctggtgtcac gccctccag tgtgcaaata agggctgctg ttgcacgac  
181 accgttcgtg gggtccctg gtgcttctat cctaatacca tcgacgtccc tccagaagag  
241 gagtgtgaat tttag

FIGURE 6

1 atgggacggc gagacgccc gctcctggca gcgcctcg tcctgggct atgtccctg  
61 gcggggagtg agaaaccctc cccctgccag tgctccaggc tgagccccca taacaggacg  
121 aactgcggct tccctgaaat caccagtgcac cagtgtttg acaatggatg ctgttcgac  
181 tccagtgtaa ctgggtccc ctgggtttc cacccctcc caaagcaaga gtcggatcag  
241 tgcgtcatgg aggtctcaga ccgaagaaac tgtggctacc cgggcatcag ccccgaggaa  
301 tgcgcctctc ggaagtgtcg cttctccaac ttcatcttg aagtgcctcg gtgcttctc  
361 ccgaagtctg tggaaagactg ccattactaa

FIGURE 7

(page 1 of 2)

1 atgctgggc tggcctggc cttgctgtcc tccagctctg ctgaggagta cgtggcctg  
61 tgtgagtaact gcccgtactg ccccggtggc agggtggcgc tgaaggaaag ggatccagga  
121 taagggggga ttctgcatttc atttaataat ggccacctgt cacatataca ctccccctg  
181 cgctagccct ttgaagtggg tctttattgt ccccatattca cagacaagga aaccgaggct  
241 cagagaaagt taacaactta tccaaggcag ccctgcccag tctgtgttga aatcagggtt  
301 tgagcctgag cccatccccat atgacccat agccatctt gctggagatt tctaaattac  
361 aatataggtc tttatgcatt gttccacatt tacaagaaa aaggaaagat gcaggagaaa  
421 aaccctgact tcagaacact gtcaataccg gcaggcacaa ggttcattta gccattgcatt  
481 agcaaccctg ccatggggtg tggctgctcc attaacccaa gtttgaagga atgagggcat  
541 ggctttatc tgggtgtctt ctgagcagg tcaaaggcag tggttccga acttgcagcc  
601 cattagaatc acctggagag cttaaaaat cctaatgctt ggggcacacc agttacatca  
661 gggcatctcc aggcaagatc caggcctcag ctgtttgtt ttgagatagc cttgctttgt  
721 cactcactgc tggagtgca gggcacaatc tcagctca gcaacctccg cctccctgggt  
781 tcaagcaatt cttgtgcctc ggcttcaagt agctggatt acaggcatgc accaccatgc  
841 ccagctaatt ttttgattt ttagtagaga tggagttcg ctatgttgc caagctggc  
901 tcaaactcct ggcctcaagt gatcctcctg cttggcctc ccaaagtgtt ggaattacag  
961 gtgttaagcca ccatgcccag ccaacgtcag tcattttaa agctctgcag ctgattccag  
1021 tgtgagcgaa gtttggatgc caggaggata agcaattacg gactgggagc aagagaaggg  
1081 aatgttaagac actgcacgtg attgccattt tcctaaggaa atactcagtt cgttaatgaa  
1141 acgcagtgaa cttctgctgc acatacagac atagaggctt gcctgaaaca taaaaatatt  
1201 ggggactgaa ggatgtcccg ggagggtggg acatgctaa caattcagga aggggagatg  
1261 cagaaaaaaag tgaaaagcag gcagcatgcg ttgcaatgat ctctatggcg tgtgcctc  
1321 ctgtcacggg tttcatttaa aacaaagggg caaggtttt gttgtcaaacc aatgaagggt  
1381 aactttgttt ctgggttcaa gggaccccg attcccccagg gttcctgcc agctggaagg  
1441 tacccaggc tctatgtgac ttcccgagaa ggtgataaga gcgtgccaag gagaaagaca  
1501 cttaggcaaa tggccagagt ccccgagctg agcatttaac agactgcctc tcttaata  
1561 ttcacaggga aagtgcattt tcctaagggc gagggttca gcagtgggtt aactccgg  
1621 ggtggggcgg agcgggagga tgcaaactt caaagtgaag caaacacact caccgcagcc  
1681 cagcaaggc tctggcagct gacagggtt tgtctggac agctgcaaac cagtgtgccg  
1741 tgccagccaa ggacagggtg gactgcggct accccccattt caccggcaag gagtgcaca  
1801 accggggctg ctgctttgac tccaggatcc ctggagtgcc ttgggtttc aagccctgc  
1861 aggaagcagg taaggccccat gtggcatgt ggtctggcc cagcccccata aggcagggg  
1921 tctcaggggcc tccctgtcct ttctggctg gagatggagg cacaaggacc ccaggaagcc  
1981 acacacacac acctgttcca aggccctcaga gcagaggctt cacacttgg gcagccatgg  
2041 ccagggctg tcctcttctg tcccctttat gtaaaacata aaagcaattt tttcaaaaag  
2101 gtgttcaaaa tgatggcatc gcatagaggg aactgattt gtaactattt ttgagagaag  
2161 tggaaacgc taggtgtgga aagccgggccc gactttggg ctgttttgc aaatccggccc  
2221 cccagagtct tgcatttgtt ggcattccctt acacagacgg caggcggcc cagccctaga  
2281 cgtcaggcct cggtgccaca ccccacctcc cccactctgc ccccccacaag ggtcatctcc  
2341 tctccctctc tctggcgtgg tggaggcag gtgcaggcga accaccctgg gggttccctc  
2401 cccaggggcg gagagcctgc gtgctgtgc ggtAACAGAT ggccctgcac acgggtttgc  
2461 caccctggct ccaccaggct tagctggccc acatgtggg tggggcgtt ggctataagc  
2521 catctgccat gtccaagtgc cagtcagcc cccacgaagg ccgcacctgc gtgaggtacc  
2581 ttccctggaaac cagcatccag agggccctctt ttgccttgc gtccttagggt gaaatgcggg  
2641 aggctgagtc ctgctggccc cggctccctg atcaatgatg ggccctgccc cagggcctcc

FIGURE 7

(page 2 of 2)

2701 ctccaccctc cccagcaagt ccagggtagg ggtgggggtg ggggtccaga gaaggccagg  
2761 agagagaggg gtctggctac tgtccactgc cggtcctgtt ctttcagctc cactggaact  
2821 acactctcct ctgagtgcc a gccatggccc tgccaaaggcc catctcgctt gttatctgcc  
2881 tgatccctgg gtcccactat cttgcttagc a acccgaggt ggaaatcttg gctattcccc  
2941 catgtggtgg ggactcaaca ctccccggtg actctggga ggaggcagca ctaggtgctg  
3001 gccttggago ctgcctgac cttggaaagc tggcagcgt gggtgagag agactgctca  
3061 cacaagcctt tgctctgttt gcagaatgca cttctgagg cacctccagc tgccccggc  
3121 cgggggatgc gaggctcgga gcacccttgc ccggctgtga ttgctgccag gcaactgttca  
3181 tctcagctt tctgtccctt tgctcccgcc a aagcgcttct gctgaaagtt catatctgga  
3241 gcctgatgtc ttaacgaata aaggcccatt gctccaccccg

FIGURE 8

(page 1 of 2)

1 ccctgggtg cagctgagct agacatggga cggcgagacg cccagctcct ggcagcgctc  
61 ctcgtcctgg ggctatgtgc cctggcgaaa agtgagaaac cctgttaagtg aaggagaggg  
121 tcttttatg tgctttctt atttctcta aagaaaaaaa aaaagcacaa ccataaatta  
181 acttgagagg ggaaatggct ataaaggcat ctggcaatgt gtgttgtca catggattt  
241 gccactgctc aggagggtgg ctccaagaag ggcctccctc ctagggaaag gctgagtgac  
301 ggcaggtgtc agcgggcccc gtgtcgggcc aggaggcat tcccaccaag ggtccttgg  
361 gtcccagagc actcacctct cgcctggatc ttggccttgg gtccatctgt tcaccctcct  
421 ctaggagggt tttgttttg ttttttccg agacaggatc tggcttgcc gcccaggcag  
481 gagtgcagtg gtgtgatctt ggctcaactgc aacctctgcc tcccaggctc aagtgatcct  
541 cccacccatcg ccgcctgagt agctgaaacc acagttgtgg accatcatgc ccggccaatt  
601 ttttttttg tattgtttgt agagatgggg tttcgacatg ttgcccagga tggcttgaa  
661 ctcctgagct caagcaatct gcccgcctcg gcttcctaaa gtgctggat tataaggatg  
721 agccaccatg cctggctttt tttttttt cctttaaac taatataaca atttcagcaa  
781 agccctatcg gcttctcagg aggaaaccgc attgcttaaa tatggcaag ataagacttt  
841 gtgtttctct atgtggcaac aagacagtag aggcattcccc tagaacctct gagagaagga  
901 gcagtgtggc ctgggttacc aggggtgggc cgactgaggg tctttccaca gccccctgcc  
961 agtgctccag gctgagcccc cataacagga cgaactgcgg cttccctgga atcaccagt  
1021 accagtgttt tgacaatggc tgctgttgc actccagtgt cactgggtc ccctgggtt  
1081 tccacccctt cccaaagcaa ggtaatctc cagggatct tcctggcca gcagctggca  
1141 acccaggacc cagttcaca ggcggagccc agagcagggg ccggaggagg cccagttgct  
1201 agtcttagggt tagcctgggt gggtagtct cgagctagcc ccggttgggt agtctgggc  
1261 tagcccaggt tggtagtct agagctagcc caggttgggt agtctgggc tagccaggt  
1321 tggtagtct gggctagcc caggttgggt agtctaggc tagttaggc tagtagtct  
1381 aaggctagcc caggttgggt agtttggagc tagcgcaggt tggtagtct gggctagta  
1441 gcccaggttg gttagcctgg agctagccca ggttggtag tctaggcgtc gcgtaggctg  
1501 gttagtcctgg ggctagccca ggttggtag tctggagcta gcccagggtg gttagtcctgg  
1561 ggctagtagc ccaggttgggt tagtctgggg ctagcccagg ttggtagtgc tagggctagt  
1621 gtaggctagt tagtcttaggg ctagcccagg ttagtttagt tggagctagc acaggtttagt  
1681 tagtctgggg ctagtagcct aggttggta gtctggagct agcccaagtt gttagtc  
1741 gggctagcat aggctggta gtctggggct agtagcctag gtttggtagt ctggagctag  
1801 cccaggttgg ttagtctagg gctagcgtag gctggtagt ctagggctag cccaggttgg  
1861 ttaatcgag ctagcccagg ttggtagtc tggagctagc ccaggttgg tagtctgagg  
1921 ctagtagccc aggttggta gtctggggct agcccaagggt tggtagtctc gagctagccc  
1981 aggttggta gtctggagct agcccaagggt ggttagtctg ggactagct ggactgctag  
2041 tctagaggta gcctagagga ctgctagtct agaggttagtc tagggctagc ccaggttgg  
2101 tagtctgggg ctagcccattt ttggtagtc ttagactagc ctggactgct agtctagagg  
2161 tagcccaggt tggtagtct ggtactagcc tggactgtta gtctagaggt agcccaagggt  
2221 ggttaggtt gttagtcctgg gactagtctg gactgttagt ctagaggttag cccaggttgg  
2281 ttagtctggg actagcctgg actgttagtc tagaggtagc ccagattgg tagtctggga  
2341 ctagtctgga ctgctagtct agaggttagcc caggttgggt agcctggggc cagcctggac  
2401 tggtagtcta gaggttaacc aggtcagcca acagttagat gaaaatttcc cacctaccct  
2461 gtttctacac tggtagtctttt ttcaacagac atgtgtgtgt ggagccatca gtttacttt  
2521 agttgagaaa aaaatatata tatatatagt aggtcctcctc tagttttga agtgtgactt  
2581 ctgaagaagc ttccatgggg aaatgaaggt attaatagg acagcagtaa cataaggcgt  
2641 gacagccctc aaatgttagg gaaggaagtg aagccttcta ggttctttg ggagttagt

FIGURE 8

(page 2 of 2)

2701 ttatgttagt gcacgggatc aggaccgaag ttgttaacgcc gacgagtgc caaaggaagg  
2761 ttgtgtgtgt gtcgtgcacc tgtgtgcgtg gaaccaggca cgtccctctgg agaaggagga  
2821 ttcatccccca agattgttgc tgggaggcct gctggggccc gcagggaaac caggcagatg  
2881 gtggattgtt cacgagcgcc cactgaatgg cagtgtctt ggaaatcaat accatgtcca  
2941 aacgctttcc atcttaccaa ggtgccaca aacctttct catcttgcc cgggggacca  
3001 ccccatttac tgagaacact gagtcccag aggcaaaatg atttcccaa ggcggggac  
3061 tccagagctt ctgactgtga ccacccaca tgggccccac cttcgccgag gacaggccag  
3121 ccaagcgtcg ctggggccga cacttccaca gtccccgggg gaggcggtcc cagggccga  
3181 cacttccaca gtccccgggg gaggccgtcc cggggatgc tgccccaggc agcacctcat  
3241 gatccacgga ggctgcaaat cagcgctgtc ctcagaggag gaagggtgg agcttccag  
3301 ggcacagcag gcctgactgg gtctcggtgc tgtgcctgtc ccatggcaga gtcggatcag  
3361 tgcgtcatgg aggtctcaga ccgaagaaaac tgtggctacc cgggcattcag ccccgaggaa  
3421 tgcgcctctc ggaagtgtcg cttctccaac ttcatcttg aagtgcctg gtgcctctc  
3481 ccgaagtctg tggaaaggtaa cgtcgctgtg ggactctctg tctggttccc ggacaccatg  
3541 attcctcctc cgtccgtaga ggtgggtgc agggagggga gtcgcctcgc agcctcagtg  
3601 ccatcgaggg cagggccct gcctcctatg ggattctgaa ggcaattcca gaatgttctt  
3661 ggcaaagaca gcgtctttc aataagttt tagcctccag cattgccact gcgtcatctg  
3721 tgcgtgtct agaaacagcg gtcatccct gttgcctccc caggtgtgc aacgttcaga  
3781 ggcgttgcct gtttattgc aagccatct gcattggag gctactgagt gtcttgact  
3841 gtgcgtggta ccagagaggg cccaaactcaa gcagacctgg ccccttctcc cgtggcttcc  
3901 ccgttctccc ccacatgacc ccgaatgaca aacctcatcc acaacgtcct gtcggggca  
3961 gtcccgggag ggtcccgccg gcagaggtga acgggtccac ttctccacc cgcttagtga  
4021 tagtgcgttc ctgactcgga gtgtggcgag gtaaaaaaaag accaagcaga tccagggaaa  
4081 tggggaaaga gctactggcc cttgaaggat gcctttctt ttccctttgt taggatatca  
4141 aagcactcca aagagcgaaa tatttcatgt tcaggattt ccgagtgatt tttttatgt  
4201 gacctaaagg tccacctaga aaatgttcac ttgtctgggg agaatgcgcc ccacagagga  
4261 aactctggcc tgggtggga agatttggc ccttacacc ccctccccgg gaaaggagct  
4321 ccttcttcag taggaagctc ctggccaaag tgcgtgcacgc ccaccccagc ttgcagcct  
4381 aggcaactccc atttctgggg ttcccttacc aaccatctt cattaaact tctagactgc  
4441 cattactaag agaggcttgt tccagaggat gcatctggct caccgggtgt tccgaaacca  
4501 aagaagaaac ttgccttat cagtttcata ttcatgaaa tcctgggttt tcttaaccat  
4561 ctttccctca tttcaatgg tttaacatat aatttcttta aataaaaccc taaaaatctg  
4621 ct

FIGURE 9

(page 1 of 2)

1 atccctgact cggggtcgcc tttggagcag agaggaggca atggccacca tggagaacaa  
 61 ggtgatctgc gccctggtcc tggtgtccat gctggccctc ggcaccctgg ccgaggccc  
 121 gacaggtaag gcgtgttct tcctgctctg tggggccaca gccagctctg gcagcctcc  
 181 ccaggagcca ctgtttaca tacatattt tgagcacctg ttttgtgcca ggtgctgttc  
 241 taggcctta aaagtatac caatttacag gatcgccaaa agcaggtgga gagtaactca  
 301 gggtggcagg gccccggag accttcgaga agtgcgacga ggagggggct gccttcagtc  
 361 ggggctgttt tcctgtgtta ggaagactat acaatcctcc caagtgtcat gtttcaaaga  
 421 ggaagtgttg gcgtggggtc tcagaatagt gctttgact gttcatgcca acatctcccc  
 481 caggggcaga ccctcccaag gcccattccag ataggccaa atgcccgtcc cagtgtatggc  
 541 cacctggag accctctccc acaggcccga atgcccgtcc cagtgggtgc caactggag  
 601 accctctcct acagggtcct gggctccct gggatccatg ctctgggagt caaagccacc  
 661 tctctcatga gtgcgtggct ggcaacccat attccctggt gttgtcaagt ggatcggttg  
 721 ccctgggtcc ttcttagggag tggaggagga ggccatttt gcttccttgg gaagtgttg  
 781 catctcaact ccttacctg cagaatggat caacggcttg cccttagggct gtcagggaaat  
 841 gctgtgtggc agcatctgctg acttgcactt tgccagctgt ggggagctga ataacttatt  
 901 tgccgttatt aggtacagtt tcaaggtggg ggcaggagaa agggcttct acgtttccaa  
 961 agcaagggtt tccagagagg cctgaagagg gagcgcccgag tgggtgtgtc cgtccccca  
 1021 ctgcctcca gccacctt gatctctgtc gtgggttacc gggcctgagg ggtgggttg  
 1081 ggcagcgtag aagagcagcc agcattggc tgcagtgggaa agaccccaa gcccattggca  
 1141 gggagcgggg gagctttgga acccgagaga ggaagtggcc tcgggtgtaca gaacgaactg  
 1201 ggtgggtccc cgtgtggcc acccccaggc ccatctgcct ggcgccttgc ccccacccca  
 1261 gccccagct ctgccccctg tgctgtgggaa tcacagaggc cgtggcaaacc tcccccccc  
 1321 accccacaca ccctctggct caaggctcag agcgtcttgc cgggtcactc aggtccatga  
 1381 tcctgttaca actgaaatct agaaaattgt gattacagtt tagtgcattc gtgtgtggaa  
 1441 accatttcca tttatttcca tcatgcgaca aagacaaagc ggggtggcaaa gacagagtct  
 1501 gccggaggca gagcaccggg gctggaaatc ttcctccctg aggaggaaac ccccccggacc  
 1561 cccaggatga tgatctccc tcaccacggg gcctcttgc acccccacag tgtcccggg  
 1621 gt'gggcgtatg atcaccctca cgtcgcgtatg gatccagacc ccaggagggc aagggtcccc  
 1681 tggaaagctgc tgggcagcgg gagctgaaca cggatccttc ccagcaagcc aggaacactt  
 1741 tctccaaaga catctcgagg cagtcctga tagcaaagca gacaagagaa cagccctct  
 1801 cggcctcccc tggggcgccc tcacctgagc cagtgtggcc agactgagtt cctccctcc  
 1861 tatgccccaa ggcaggagaca gggaccggag ggtgctctgg gctcctctt cacccttgc  
 1921 tgcaggctgt caaccaccag atcctaatacg gttgcttct gagacctttg attcccgcca  
 1981 gctcagagcc tgaagctctg gtgttagaac ctcttcata agatcctgcg gcagccccc  
 2041 gccagccca tctgtccacg tgccttcctc ctctagatcc ctttcctcac tgcctgtctt  
 2101 caagctgtt cacagctgt accctctgtc ggctcctctt agaccacccc acccggtct  
 2161 ctcacccctac ctgcaatggg tttccacctc ctgaacacac ctgggtctct ggaatggcct  
 2221 ttgcccattgc ggctccatct tcacctggtg aacctctcc tgcaggaggc cccctgtctt  
 2281 ttttcaacct gcttgcatt ggctctccg gggagtgccc taccgggttg gttaccctgg  
 2341 gcaccctggg acgatggcct tgcgttgtct cgcacatgtt cttgccttcc tcctccatca  
 2401 gatccttaga ctctttttt ttttttttg agatggagtc ttgctctgtc actcaggctg  
 2461 gagtgcaatg gtgcgtatctt ggctcaactac aacctctgcc tcctgggttc aagtgattct  
 2521 cctgcctcag cctcccaagt agctgggatt acagacgtgt gccacaatgc ccgcctaatt  
 2581 ttttgttatt ttagtagaga tggggcttca ccattttggt caggctggtc ttgaactcct  
 2641 gacctcaagt gattcacctc ctgcagcctc ccaaagtgtc gggattacag gcatgagcct  
 2701 gggcccaagat atttagactc ttattaatga ctgcctgtt gggctctctt

FIGURE 9

(page 2 of 2)

2761 cacctggcac agtgcctggc tttgccatg ctagctccca cttctcatgc acacaaatgg  
2821 tgctcagtaa atatttatgt attgagtaaa atttataat catttgtga aattaaaaag  
2881 tgaataaata agttacctag aaagatgcaa agtccacaaa cctggggcac cttgcatttt  
2941 ccctgagcgt aatgttgca catcaggatg tgaggaccac gtctccctct catgtcctga  
3001 gggtttata tccgcctcac tggacagttg ctgatgtcat tggagaagga agctggatgg  
3061 gtgtgtgcat gataacatca aggaattcag cccacaactt actttgcttc ttacctgtgc  
3121 actttcagag acgtgtacag tggccccccg taaaagacag aattgtggtt ttctgggtgt  
3181 cacgcctcc cagtgtcaa ataaggctg ctgttcgac gacaccgttc gtgggtccc  
3241 ctggtgcttc tatcctaata ccatcgacgt ccctccagaa ggtatggcct ttttatacga  
3301 tgggttctga agatttagaa ttagttagaa aagtcattha agactacaga ggctctgatc  
3361 agcatcacca gctatgcctt tacacagagt cacggccgcc agtgggttg caatgggtta  
3421 gcctgagtca ggctgcattc aggtccagga atagaaaggc agggctaagg gacttggaa  
3481 gaaacctgat ttccccccgg cttctcttca catctctaac caaaaggctg ggaagagcca  
3541 ctgttggtaa cgctttctag cttgcctagg atagaggggg aaggcatgac gaaatctgaa  
3601 gacatttcat gtattcttt ttttttttt tttttgaaat ggagtctcgc tccgttgc  
3661 ctgagctgga gtgcaatggt gcgatctgg ctcactgcaa tctctgcctc ctgagttcaa  
3721 cctcagcttc ctagtagctg agattacagg tgtgtgccac tacgcccagc taaattttt  
3781 ttgttatttt agtataagacg gggtttcacc atgttgccca gaccggctt gaactcttga  
3841 cctcaggtga tctgcccggc tcagcctccc agagagctgg gattacaggc gtgagccacc  
3901 gtgcccggct gacagttcat gttttctaaa gaatgtgcct atggatactt taaagtaaaa  
3961 actctgtaat tgtttaaatg taaaagaaaa tttttatcct cactaaagca tctcttctc  
4021 cctccccctc acccctgtag aggagtgtga attttagaca cttctgcagg gatctgc  
4081 catcctgacg cggtgccgtc cccagcacgg tgattagtcc cagagctgg ctgccac  
4141 caccggacac ctcagacacg cttctgcagc tgtgcctcgg ctcacaacac agattgactg  
4201 ctctgacttt gactactcaa aattggccta aaaattaaaa gagatcgata tt

## SEQUENCE LISTING

<110> The General Hospital Corporation

<120> Methods and Compositions for Treating  
Oral and Esophageal Lesions

<130> 50206/002WO2

<150> US 60/286,240

<151> 2001-04-24

<160> 9

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 73

<212> PRT

<213> Homo sapien

<400> 1

Met Leu Gly Leu Val Leu Ala Leu Leu Ser Ser Ser Ser Ala Glu Glu  
1 5 10 15  
Tyr Val Gly Leu Ser Ala Asn Gln Cys Ala Val Pro Ala Lys Asp Arg  
20 25 30  
Val Asp Cys Gly Tyr Pro His Val Thr Pro Lys Glu Cys Asn Asn Arg  
35 40 45  
Gly Cys Cys Phe Asp Ser Arg Ile Pro Gly Val Pro Trp Cys Phe Lys  
50 55 60  
Pro Leu Gln Glu Ala Glu Cys Thr Phe  
65 70

<210> 2

<211> 84

<212> PRT

<213> Homo sapien

<400> 2

Met Ala Thr Met Glu Asn Lys Val Ile Cys Ala Leu Val Leu Val Ser  
1 5 10 15  
Met Leu Ala Leu Gly Thr Leu Ala Glu Ala Gln Thr Glu Thr Cys Thr  
20 25 30  
Val Ala Pro Arg Glu Arg Gln Asn Cys Gly Phe Pro Gly Val Thr Pro  
35 40 45  
Ser Gln Cys Ala Asn Lys Gly Cys Cys Phe Asp Asp Thr Val Arg Gly  
50 55 60  
Val Pro Trp Cys Phe Tyr Pro Asn Thr Ile Asp Val Pro Pro Glu Glu  
65 70 75 80  
Glu Cys Glu Phe

<210> 3

<211> 106

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 3

Glu	Lys	Pro	Ser	Pro	Cys	Gln	Cys	Ser	Arg	Leu	Ser	Pro	His	Asn	Arg
1				5					10					15	
Thr	Asn	Cys	Gly	Phe	Pro	Gly	Ile	Thr	Ser	Asp	Gln	Cys	Phe	Asp	Asn
				20				25					30		
Gly	Cys	Cys	Phe	Asp	Ser	Ser	Val	Thr	Gly	Val	Pro	Trp	Cys	Phe	His
				35			40					45			
Pro	Leu	Pro	Lys	Gln	Glu	Ser	Asp	Gln	Cys	Val	Met	Glu	Val	Ser	Asp
				50			55				60				
Arg	Arg	Asn	Cys	Gly	Tyr	Pro	Gly	Ile	Ser	Pro	Glu	Glu	Cys	Ala	Ser
65				70				75				80			
Arg	Lys	Cys	Cys	Phe	Ser	Asn	Phe	Ile	Phe	Glu	Val	Pro	Trp	Cys	Phe
				85				90				95			
Phe	Pro	Asn	Ser	Val	Glu	Asp	Cys	His	Tyr						
				100				105							

&lt;210&gt; 4

&lt;211&gt; 222

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 4

atgctggggc	tggtcctggc	cttgctgtcc	tccagctctg	ctgaggagta	cgtgggcctg	60
tctgcaaacc	agtgtgccgt	gccagccaag	gacagggtgg	actgcggcta	cccccatgtc	120
acccccaagg	agtgcaacaa	ccggggctgc	tgcttgact	ccaggatccc	tggagtgcct	180
tggtgtttca	agcccctgca	ggaagcagaa	tgcacccct	ga		222

&lt;210&gt; 5

&lt;211&gt; 255

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 5

atggccacca	tggagaacaa	ggtgatctgc	gccctggtcc	tggtgtccat	gctggccctc	60
ggcacccctgg	ccgaggccca	gacagagacg	tgtacagtgg	ccccccgtga	aagacagaat	120
tgtggttttc	ctgggtgtcac	gccctcccag	tgtgcaaata	agggctgctg	tttcgacgac	180
accgttcgtg	gggtcccctg	gtgcttctat	cctaatacca	tcgacgtccc	tccagaagag	240
gagtgtaat	tttag					255

&lt;210&gt; 6

&lt;211&gt; 390

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 6

atgggacggc	gagacgcca	gctcctggca	gcgcctcctcg	tcctggggct	atgtgccctg	60
gcggggagtg	agaaaaccctc	cccctgcccag	tgctccaggc	tgagccccca	taacaggacg	120
aactgcggct	tccctggaat	caccagtgac	cagtgtttg	acaatggatg	ctgtttcgac	180
tccagtgtca	ctggggtccc	ctgggtttc	cacccctcc	caaagcaaga	gtcgatcg	240
tgcgatcg	aggctcaga	ccgaagaaac	tgtggctacc	cgggcatcg	ccccgaggaa	300
tgcgcccttc	ggaagtgctg	cttctccaac	ttcatcttg	aagtgccctg	gtgcttcttc	360
ccgaagtctg	tggaagactg	ccattactaa				390

&lt;210&gt; 7

<211> 3280  
 <212> DNA  
 <213> Homo sapien

<400> 7

atgctgggc	tggcctggc	cttgctgtcc	tccagctctg	ctgaggagta	cgtggcctg	60
tgtgagtact	gccctgactg	ccccgggtggc	agggtgggcg	tgaaggaaag	ggatccagga	120
taagggggga	ttctgcattc	attnataat	ggccacctgt	cacatataca	cttttcctg	180
cgctagccct	ttgaagtggg	tcttattgt	ccccatttca	cagacaagga	aaccgaggct	240
cagagaaaagt	taacaactta	tccaaggcag	ccctgcccag	tctgtgttga	aatcagggtt	300
tgagcctgag	cccatcccct	atgacccat	agccatctt	gctggagatt	tctaaattac	360
aatataggtc	tttatgcatt	gttccacatt	tacaaagaaa	aaggaaagat	gcaggagaaa	420
aaccctgact	tcagaacact	gtcaataccg	gcaggcacaa	gttcatatta	gccattgcata	480
agcaaccctg	ccatgggtg	tggctgctcc	attaacccaa	gtttgaagga	atgagggcat	540
ggctttatc	tgggtgtctt	ctgagcaggg	tcaaaggcag	tggttcccg	acttgcagcc	600
cattagaatc	acctggagag	ctttaaaaat	cctaattgtt	ggggcacacc	agttacatca	660
gggcatctcc	aggcaagatc	caggcctcag	ctgtttgtt	ttgagatagc	cttgctttgt	720
cactcaactc	tggagtgcag	tggcacaatc	tcagctca	gcaacctccg	cctcctgggt	780
tcaagcaatt	cttgcgcctc	ggcttcaagt	agctggatt	acaggcatgc	accaccatgc	840
ccagctaatt	ttttggattt	tttagtagaga	tggagttcg	ctatgttgc	caagctggc	900
tcaaactcct	ggcctaagt	gatcctcctg	ccttggcctc	ccaaagtgt	ggaattacag	960
gtgttaagcca	ccatggccag	ccaacgtcag	tcattttaa	agctctgcag	ctgattccag	1020
tgtgagcgaa	gtttggatgc	caggaggata	agcaattacg	gactggagc	aagagaaggg	1080
aatgttaagac	actgcacgtg	attgcattt	tcctaaggaa	atactcagtt	cgttaatgaa	1140
acgcagtgaa	cttctgctgc	acatacagac	atagaggctt	gcctgaaaca	tgaaaatatt	1200
ggggactgaa	ggatgtccc	ggaggggtgg	acatgtcaa	caattcagga	agggagatg	1260
cagaaaaaaag	tgaaaagcag	gcagcatgcg	ttgcaatgat	ctctatggcg	tgtgcctctc	1320
ctgtcacgggt	tttcattttaa	aacaaagggg	caaggtttg	ttggtcaaac	aatgaagggt	1380
aactttgtt	ctgggttcaa	gggacccag	attccccagg	gttccctgcc	agctggaagg	1440
tacccagggtc	cgtatgtgac	ttcccgagaa	ggtgataaga	gcgtgccaag	gagaaagaca	1500
cttaggcaaa	tggccagagt	ccccgagctg	agcatattaac	agactgcctc	tctttaata	1560
ttcacaggg	aagtgcacat	tcctaagggc	gagggttca	gcagtggttg	aactcggcgg	1620
ggtggggcgg	agcgggagga	tgcaaacttg	caaagtgaag	caaacacact	caccgcagcc	1680
cagcaaggc	tctggcagct	gacaggcctt	tgtctggac	agctgcaaacc	cagtgtgcgg	1740
tgccagccaa	ggacagggtg	gactgcggct	accccatgt	cacccccaag	gagtgcaaca	1800
accggggctg	ctgctttgac	tccaggatcc	ctggagtgcc	ttgggttttc	aagccctgc	1860
aggaagcagg	taaggcccc	gtggcatcgt	ggtctggcc	cagccccata	aggcaggggg	1920
tctcagggcc	tccctgtcct	ttctgggctg	gagatggagg	cacaaggacc	ccaggaagcc	1980
acacacacac	acctgttcca	aggcctcaga	gcagaggctt	cacacttagg	gcagccatgg	2040
ccaggggctg	tcctttctg	tcccccttta	gtaaaacata	aaagcaattt	tttcaaaaag	2100
gtgttcaaaa	tgtatggcatc	gcatagaggg	aactgattt	gtaactattc	ttgagagaag	2160
tggaaacgca	tagtgtgga	aagccgggccc	gacttttggg	ctgttttgc	aaatcgcccc	2220
cccagagtct	tgtcatttgc	ggcatccccct	acacagacgg	caggcggtcc	cagccctaga	2280
cgtcaggcct	cggtgcacaca	ccccacctcc	cccactctgc	ccccccacaag	ggtcatctcc	2340
tctccctctc	tctgccgtgg	tggagggcag	gtgcaggcga	accaccctgg	gggttccctc	2400
cccagggcgc	gagagcctgc	gtgctgtgcg	ggttaacagat	ggccctgcac	acgggtttgc	2460
caccctggct	ccaccaggct	tagctgcccc	acatcggtgg	tggggcgatt	ggctataago	2520
catctgccat	gtccaagtgc	cagctcagcc	cccacgaagg	ccgcacctgc	gtgaggtacc	2580
ttcctggaaac	cagcatccag	aggggcctt	cttgccttt	gtccttagggt	gaaatgcggg	2640
aggctgagtc	ctgctggccc	cggctccctg	atcaatgatg	ggcccttgcc	cagggcctcc	2700
cttcaccctc	cccagcaagt	ccagggtagg	ggtgggggtg	gggttccaga	gaaggccagg	2760
agagagaggg	gtctggctac	tgtccactgc	cggtcctgtt	cttcagctc	cactggaact	2820
acactctcct	ctgagtgcca	gccatggccc	tgccaaggcc	catctcgctt	gttatctgca	2880
tgatccctgg	gtcccactat	ttgcttagc	aacccgaggt	ggaaatcttg	gttattcccc	2940
catgtggtgg	ggactcaaca	ctccccgggt	actctgggg	ggaggcagca	ctaggtgctg	3000
gccttggagc	ctgcccgtac	cttgggaagc	tgggcagcgt	gggtggagag	agactgctca	3060
cacaagcctt	tgctctgttt	gcagaatgca	ccttctgagg	cacccctcagc	tgccccccggc	3120
cggggatgc	gaggctcgga	gcacccttgc	ccggctgtga	ttgctgccag	gcactgttca	3180

tctcagctt tctgtccctt tgctccggc aagcgcttct gctgaaagtt catatctgga 3240  
 gcctgatgtc ttaacgaata aaggcccatt gctccaccccg 3280

<210> 8  
 <211> 4623  
 <212> DNA  
 <213> Homo sapien

<400> 8

dccctgggt gcagctgagc tagacatggg acggcgagac gcccagctcc tggcagcgct 60  
 cctcgctcctg gggctatgtg ccctggcggt gagtgagaaa ccctgttaatg gaaggagagg 120  
 gtcttttat gtgcattctt tatttctctt aaagaaaaaa aaaaagcaca accataaatt 180  
 aacttgagag gggaatggc tataaaggca tctggcaatg tgtgttgttc acatggatt 240  
 tgccactgct caggagggtg gctccaagaa gggcctccct cctaggaaa ggctgagtga 300  
 cggcaggtgt cagcgggccc cgtgtcggc caggaggca ttcccaccaa gggtccttgg 360  
 agtcccagag cactcaccc tgcctggat cttggccttg ggtccatctg ttcaccctcc 420  
 tctaggaggg tttttttttt gtttttttcc gagacaggat ctggctttgc cgcccaggca 480  
 ggagtgcagt ggtgtatct tggctcactg caacctctgc ctcccaggct caagtgtatcc 540  
 tcccaccta gccgcctgag tagctgaaac cacagttgtg gaccatcatg cccggccaat 600  
 tttttttttt gtattgttg tagagatggg gtttcgacat gttgccagg atggcttga 660  
 actcctgago tcaagcaatc tgccgcctc ggcttcctaa agtgcggaa ttataaggtat 720  
 gagccaccat gcctggctt tttttttttt tccttttaaa ctaatataac aatttcagca 780  
 aagccctatc ggcttcctcag gaggaaaccg cattgctaa atatggcaa gataagactt 840  
 tgtgtttctc tatgtggcaa caagacagta gaggcatccc ctagaacctc tgagagaagg 900  
 agcagtgtgg tctgggttac caggggtggg ccgactgagg gtcttccac agccccctgc 960  
 cagtgcctca ggctgagccc ccataacagg acgaactgcg gctccctgg aatcaccagt 1020  
 gaccagtgtt ttgacaatgg atgctgttc gactccagtg tcactgggt cccctgggt 1080  
 ttccacccccc tcccaaagca agttaatctt ccagggatac ttccctggcc agcagctggc 1140  
 aaccaggac ccagcttcac aggccggagcc cagagcaggg gcccggaggag gcccagttgc 1200  
 tagtcttaggg ttagcctggg tgggttagtc tcgagctagc cccgggttgt tagtctgggg 1260  
 ctagcccagg ttggtagtc tagagctagc ccaggttgt tagtctgggg ctagcccagg 1320  
 ttggtagtc tggggctagc ccaggttgt tagtcttaggg cttagttagg cttagttagc 1380  
 taaggctagc ccaggttgt tagttggag ctagcgcagg ttggtagtc tggggctagt 1440  
 agcccagggtt gtttagcctg gagctagccc aggttgtta gtctaggct agcgtaggct 1500  
 gtttagtctg gggctagccc aggttgtta gtctggagct agcccagggtt gtttagtctg 1560  
 gggctagtag cccaggttgt ttagtctggg gctagcccag gttggtagt ctagggctag 1620  
 tgtaggctag ttagtcttagg gctagcccag gtttagttagt ttggagctag cacaggttga 1680  
 ttagtctggg gctagtagcc taggttgtt agtctgggc tagtagccta gtttggtag tctggagct 1740  
 agggctagca taggctgggtt agtctgggc tagtagccta gtttggtag tctggagct 1800  
 gcccagggtt gtttagtctg ggctagctgta ggctgggtt tagcccaagt tggtagtct 1860  
 gttaatcgga gctagcccag gttggtagt ctggagctag cccaggttgt ttagtctgag 1920  
 gctagtagcc caggttgtt agtctgggc tagcccagggtt ttgttagtct ggagctagcc 1980  
 caggttgtt agtctggagc tagcccagggtt tggtagtct gggactagcc tggactgcta 2040  
 gtcttagaggt agcctagagg actgttagtc tagaggtgt cttagggctag cccaggttgt 2100  
 ttagtctggg gctagcccat gttggtagt cttagactag cctggactgc tagtcttagag 2160  
 gtagcccagg ttgttagtc tggtagtgc ctggactgtt agtctagagg tagcccagggtt 2220  
 tggtaggtt gtttagtctg ggacttagtct ggactgttag tctagaggta gcccagggtt 2280  
 gtttagtctgg gactgcctg gactgttagt cttagaggtgt cccagattgg ttagtctggg 2340  
 actagtctgg actgcttagtc tagaggttagc ccaggttgt tagcctgggg ccagcctgga 2400  
 ctgttagtct agaggttaacc caggtcagcc aacagtgaga tgaaaatttc ccacctaccc 2460  
 tggtagtctaca ctgttagttc tttcaacaga catgtgtgtg tggagccatc agttagtactt 2520  
 tagttgagaa aaaaatatat atatatatag taggtctctt ctgtttttg aagtgtact 2580  
 tctgaagaag cttccatggg gaaatgaagg tatttaatag gacagcagta acataagggc 2640  
 tgacagccct caaatgttag ggaaggaaatg gaagccttct agggttctt gggagtgagt 2700  
 tttatgttag tgcacggat caggacccaa gttgtaacgc cgacgagtgc tcaaaggaag 2760  
 gttgtgtgtg tgcgtgcac ctgtgtgcgt ggaaccaggc acgtcctctg gagaaggagg 2820  
 attcatcccc aagattgttg ctggaggct tgctggcccg cgccaggaaa ccagcagat 2880  
 ggtggattgt tcacgagcgc ccactgaatg gcagtgtctt tggaaatcaa taccatgtcc 2940

aaacgctttc catcttacca aggtgcccac aaacctttc tcatcttggc cggggggacc 3000  
 accccattta ctgagaacac tgagtccga gaggcaaaat gattccccca aggcccccca 3060  
 ctccagagct tctgactgtg accacccac atgggccccca cttcgccga ggacaggcca 3120  
 gccaagcgtc gctggggccg acactccac agtccccggg ggaggccgtc ccagggggccg 3180  
 acacttccac agtccccggg ggaggccgtc ccggggggatg ctgccccagg cagcacctca 3240  
 tgatccacgg aggctgaaa tcagcgctgc tctcagagga ggaaggggtg gagcttcca 3300  
 gggcacagca ggcctgactg ggtctcggtg ctgtgcctgt cccatggcag agtcggatca 3360  
 gtgcgtcatg gaggtctcag accgaagaaa ctgtggctac ccgggcatca gccccgagga 3420  
 atgcgcctct cggaagtgtc gcttctccaa cttcatctt gaagtgcctt ggtgcttctt 3480  
 cccgaagtct gtggaaaggta acgtcgctgt gggactctt gtctggttcc cggacaccat 3540  
 gattcctcct ccgtccgtag aggtgggtg cagggagggg agctgcctcg cagcctcagt 3600  
 gccatcgagg ccagggcccc tgcctcctat gggattctga aggcaattcc agaatgttct 3660  
 tggcaaagac agcgtcttt caataagttt atagcctcca gcattgccac tgcgtcatct 3720  
 gtgatggctc tagaaaacgc ggctcatccc tggccctcc ccaggtgttca caacgtttag 3780  
 aggcgttgcc tggtttattt caagccatc tgcatttgga ggctactgag tgtcttgcac 3840  
 tgtgctgggt accagagagg gccaactca agcagacctg gccccttctc ccgtggcttc 3900  
 cccgttctcc cccacatgac cccgaatgac aaacctcatc cacaacgtcc tgctccggc 3960  
 agtcccggga gggtcccggcc ggcagaggtg aacgggtcca cttctccac ccgcttagtg 4020  
 atagtgtgtt cctgactcggt agtgtggcga gttaaaaaaaaa gaccaagcag atccaggaaa 4080  
 atggggaaag agctactggc ctttgaagga tgcctttct tttccttttgg ttaggatatc 4140  
 aaagcactcc aaagagcgaa atatttcatg ttcaggattt tccgagtgtat ttttttatg 4200  
 tgacctaaag gtccaccttag aaaatgttca cttgtctggg gagaatgcgc cccacagagg 4260  
 aaactctggc ctgggggtggg aagatttggt cccttacac cccctcccg ggaaaggagc 4320  
 tccttcttca gtaggaagct cctggcaaa gtgatgcacg cccacccag cttcgcagcc 4380  
 taggcactcc catttctggg gttcccttac caaccatctt gcatttaaac ttctagactg 4440  
 ccattactaa gagaggctgg ttccagagga tgcatctggc tcaccgggtg ttccgaaacc 4500  
 aaagaagaaa cttcgcccta tcagcttcat acttcatgaa atcctgggtt ttcttaacca 4560  
 tcttttcctc attttcaatg gtttaacata taatttctt aaataaaacc cttaaaatct 4620  
 gct  
 4623

<210> 9  
 <211> 4252  
 <212> DNA  
 <213> Homo sapien

<400> 9  
 atccctgact cggggtcgcc tttggagcag agaggaggca atggccacca tggagaacaa 60  
 ggtgatctgc gccctggcc tgggtccat gctggccctc ggcaccttgg ccgaggccca 120  
 gacaggtaag gcgtgcttct tcctgctctg tggggccaca gccagctctg gcaggctccg 180  
 ccaggagcca ctgtttaca tacatatttt tgagcacctg ttttgcgttca ggtgctgttc 240  
 taggcctta aaagtatatac caatttacag gatcgccaaa agcaggttga gagtaactca 300  
 gggtggcagg gccccccggag accttcgaga agtgcacgaa ggagggggct gccttcagtc 360  
 ggggctgttt tcctgttta ggaagactat acaatcctcc caagtgtcat gttcaaaaga 420  
 ggaagtgttg gcgtggggtc tcagaatagt gcttttact gttcatgcac acatctcccc 480  
 caggggcaga ccctcccaag gcccattccag ataggccaa atgcctggcc cagtgtggc 540  
 cacctggag accctctccc acaggcccga atgcccgtcc cagtgggtgc caactggag 600  
 accctctcct acaggttccct gggctccctt gggatccatg ctctggagt caaagccacc 660  
 tctctcatga gtgcgtggct ggcaacccat attccctggt gttgtcaagt ggatcggttg 720  
 ccctgggtcc ttcttagggag tggaggagga ggccatttctt gttcccttgg gaagtgtttg 780  
 catctcaact ctttacctg cagaatggat caacggctcg ccctagggt gtcaggaaat 840  
 gctgtgtggc agcatctgcg acttgcactt tgccagctgt gggagctga ataacttatt 900  
 tgccgttatt aggtacagtt tcaagggtgg ggcaggagaa agggctttct acgtttccaa 960  
 agcaagggtt tccagagagg cctgaagagg gagcgcccgag tgggtctgtc cgtgccccca 1020  
 ctgccctcca gccaccttctt gatctctgct gtgggggtacc gggcctgagg ggtgggcttg 1080  
 ggcagcgttag aagagcagcc agcattggc tgcagtggaa agaccccaa gcccattggca 1140  
 gggagcgggg gagcttggaa acccgagaga ggaagtggcc tcgggttaca gaacgaactg 1200  
 ggtgggtccc cgtgctggcc acccccaggc ccatctgcct ggccttgc cccacccca 1260  
 gcccccaagct ctgccccctg tgctgtggaa tcacagaggc cgtggcaaacc tccccctcccc 1320

accccacaca ccctctggct caaggctcag agcgtcttg cgggtcaactc aggtccatga 1380  
 tcctgttaca actgaaatct agaaaattgt gattacagtt tagtcattc gtgtgtggaa 1440  
 accatttcca tttatttcca tcacgcaca aagacaaagc gggtgggcaa gacagagtct 1500  
 gccggaggca gagcaccggg gctggaaatc ttccctccctg aggaggaaac ccccccgacc 1560  
 cccaggatga tgatcctccc tcaccacggg gcctctttg acccccacag tgtcccgaaa 1620  
 gtgggcgatg atcacctca cgtcgcgtg gatccagacc ccaggaggc aaggttccca 1680  
 tggaaagctgc tgggcagcgg gagctgaaca cgatccttc ccagcaagcc aggaacactt 1740  
 tctccaaaga catctcgagg cagtcctga tagcaaagca gacaagagaa cagccctct 1800  
 cggcctcccc tggggggccc tcacctgagc cagtgtggcc agactgagtt cctccctcc 1860  
 tatgccccaa ggcaggagca gggaccggag ggtgctctgg gctccctttt caccctgc 1920  
 tgcaggctgt caaccaccag atcctaatacg gttgcttttct gagacctttg attccgcgga 1980  
 gctcagagcc tgaagctctg gtgttagaac ctcttgcata agatcctgcg gcagccccc 2040  
 gccagccccca tctgtccacg tgtcttcctc ctctagatcc ctccctcac tgcctgctt 2100  
 caagctgttt cacagttgt accctctgtc ggctcctcct agaccacccc acccggtcct 2160  
 ctcacccatc ctgcaatggg tttccacctc ctgaacacac ctgggtctct ggaatggcct 2220  
 ttgcccatgc ggctccatct tcacctggtg aacctcctcc tgcaggagc cccctgttt 2280  
 tggtaaacct gcttgcatt ggctcctccg gggagtgcct taccgggtt gttaccctgg 2340  
 gcaccctggg acgatggcct tgcggtgtct cgcacatgtt cttgccttcc tcctccatca 2400  
 gatccttaga ctctttttt ttttttttg agatggagtc ttgctctgtc actcaggctg 2460  
 gagtgcaatg gtgcgtatctt ggctcaactac aacctctgtcc tcctgggttc aagtgattct 2520  
 cctgcctcag cctcccaagt agctgggatt acagacgtgt gccacaatgc ccgcctaatt 2580  
 ttttgttattt ttagtagaga tgggggttca ccattttgtt caggctggtc ttgaactcct 2640  
 gacctaagt gattcacctc cttcagcctc ccaaagtgtt gggattacag gcatgagcct 2700  
 gggcccagat atttagactc ttattaatga cttctctgtt ttaattttct gggtctctct 2760  
 cacctggcac agtgcctggc ttttgcctatgt ctgcctccca cttctcatgc acacaaatgg 2820  
 tgctcagtaa atatttatgt attgagtaaa atttaataat catttgttga aattaaaaag 2880  
 tgaataaaata agttacctag aaagatgcaa agtccacaaa cctggggcac cttgcatttt 2940  
 ccctgagcgt aatgtttgca catcaggatg tgaggaccac gtctccctct catgcctga 3000  
 gggtttata tccgcctcac tggacagttt ctgatgtcat tggagaagga agctggatgg 3060  
 gtgtgtgcat gataacatca aggaattcag cccacaactt actttgcattc ttacctgtgc 3120  
 actttcagag acgtgtacag tggcccccgg taaaagacag aattgtggtt tccctgggtt 3180  
 cacgcctcc cagtgtcaa ataagggtcg ctgtttcgac gacaccgttc gtgggtccc 3240  
 ctggtgcttc tattcttaata ccatcgacgt ccctccagaa ggtatggct ttttatacga 3300  
 tgggttctga agatttagaa tttagtttagaa aagtcttttta agactacaga ggctctgatc 3360  
 agcatcacca gctatgcctt tacacagagt cacggccgccc agtgggtgtg caatgggta 3420  
 gcctgagtca ggctgcattc aggtccagga atagaaaaggc agggctaagg gacttggaa 3480  
 gaaacctgat ttccccccgg cttcttttca catctctaacc caaaagcctg ggaagagcca 3540  
 ctgttggtaa cgctttctag cttgcctagg atagaggggg aaggcatgac gaaatctgaa 3600  
 gacatttcat gtattttttt tttttttttt tttttgaaat ggagtctgc tccgttgc 3660  
 ctgagctgga gtgcaatggt gcgatcttgg ctcactgcaa tctctgcctc ctgagttcaa 3720  
 cctcagcttc ctagtagctg agattacagg tgggtgtccac tacgcccagc taaattttt 3780  
 ttgttattttt agtataagacg gggtttcacc atgttggcca gaccggtctt gaactcttga 3840  
 cctcaggtga tctgcccccc tcagcctccc agagagctgg gattacaggc gtgagccacc 3900  
 gtgccccggct gacagttcat gttttctaaa gaatgtgcct atggatactt taaagtaaaa 3960  
 actctgtaat tgtttaaatg tgaaagaaaa tgtttattcct cactaaagca tctcttctc 4020  
 cctcccccctc accccctgttag aggagtgtga atttttagaca cttctgcagg gatctgcctg 4080  
 catcctgacg cgggtggccgtc cccagcacgg tgatttagtcc cagagctcgg ctgcacccctc 4140  
 caccggacac ctcagacacg cttctgcagc tggcctcgg ctcacaacac agattgactg 4200  
 ctctgacttt gactactcaa aattggccta aaaattaaaa gagatcgata tt 4252

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/12891

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 38/00, 38/16

US CL : 514/2, 12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 12; 435/69.1, 91, 172.3, 320.1, 235.1; 536/27, 23.5; 530/300; 935/9, 10, 23

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,E	US 6,221,840 B1 (PODOLSKY et al) 24 April 2001 (24.04.2001), abstract, column 1, lines 25-38, column 15, lines 33-47, column 16, lines 1-5, column 27 lines 14-35, column 28, lines 13-34.	1-6, 34-38, 42
X	US 6,063,755 A (PODOLSKY et al) 16 May 2000 (16.05.2000), abstract, column 1, lines 29-33, column 3, lines 61-67, column 9, lines 31-34, column 10, lines 1-3.	1-16, 34-38, 42
A	MODLIN et al. Trefoil Peptides: Mitogens, Motogens, or Mirages? J. Clin. Gastroenterol. 1997, Vol.25 (Suppl. 1), pages S94-S100.	1-7, 10-16

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"B"	earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search  30 July 2002 (30.07.2002)	Date of mailing of the international search report  11 SEP 2002
Name and mailing address of the ISA/US  Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer  B. Dell Chism Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/12891

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Continuation Sheet

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-55 (in-part)

Remark on Protest

  

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

PCT/US02/12891

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

1. This International Preliminary Examining Authority has found greater than 1 invention claimed in the International Application covered by the claims indicated below:

This application contains more than one invention or group of inventions wherein the inventions or group of inventions consists of a method and a product:

Group I, claim(s) 1-55, drawn to methods of treatment by trefoil peptide and a second therapeutic and the composition for such treatment.

However, the first invention claims a method of treatment requiring a trefoil peptide and subsequently claims three peptides of similar function but are structurally different for use in the treatment scheme. One or more of the peptides is/are known in the art (i.e. intestinal trefoil factors) (U.S. Patent No. 6,063,755) and therefore lack a special technical feature. Applicant must elect one peptide of the three. Additionally, the first invention claims a second therapeutic for use in conjunction with one of the structurally different peptides, however, the applicant claims six different classes of compounds to represent the second therapeutic wherein the classes are further divided into subgroups of therapeutics. The applicant must elect one representative for the second therapeutic. Furthermore, the first invention claims formulations for the peptide and the second therapeutic as being the same or different. The applicant needs to elect one formulation as same or different one from the other. For explanation of possible combinations see below:

1. Trefoil peptides: [A] spasmolytic polypeptide; [B] pS2; [C] intestinal trefoil factor. Applicant will receive search for [A] or Applicant must pay additional for either or both [B] and [C].
2. Second Therapeutic:
  - a. anti-inflammatory;
  - b. Antibacterial agent; (i) penicillin, (ii) cephalosporin, (iii) tetracycline, (iv) aminoglycoside, or (v) povidoneiodine.
  - c. anti-fungal agent; (i) nystatin or (ii) Amphotericin B.
  - d. anti-viral agent;
  - e. analgesic; (i) lidocaine or (ii) benzocaine.
  - f. steroid; (i) triamcinolone or (ii) hydrocortisone.
3. As to each of (a) to (f), Applicant needs to elect from (a); after first member of group additional fees for each member are required.
3. Formulation:
  - a. same formulation
  - b. different formulation

As demonstrated by the itemization above, there are 78 possible combinations of methods. Additional fees are required for searches beyond the first member or each group above. If additional members are not chosen and the required fees paid for the additional members, the first member of each group only will be searched.

Continuation of B. FIELDS SEARCHED Item 3:

**INTERNATIONAL SEARCH REPORT**

PCT/US02/12891

STN, SCISEARCH, BIOSIS, WEST, MEDLINE, TREFOIL, INTESTINAL, PEPTIDE, FACTOR, INFLAMMATORY,  
BACTERIAL, FUNGAL, ANTI, VIRAL, ANALGESIC, STEROID, LESION, ALIMENTARY, INFLAMMATION